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Abstract 
Seasonal influenza outbreaks are associated with morbidity and mortality in the United 
States. Though children are the most susceptible to influenza infection and are most 
likely to transmit the illness to others, many children are not vaccinated. The purpose of 
this study was to examine the relationship between seasonal influenza vaccination 
Advisory Committee on Immunization Practices (ACIP) recommendations, demographic 
characteristics, socioeconomic factors, and vaccine type among children over 3 
consecutive flu seasons. This quantitative cross-sectional study was guided by the social 
ecology of health model. Secondary data from 3 consecutive flu seasons (2014-2015, 
2015-2016, and 2016-2017) provided by the National Health Interview Survey was used 
for this study. Binary logistic regression and chi-square were used to analyze the data. A 
relationship between socioeconomic status, demographics (age, race, and family income) 
and vaccine type (live-attenuated influenza vaccine [LAIV]/inactivated influenza 
vaccine) was established among U.S. children; those who received LAIV were most 
likely to be White elementary school age children with a higher family income. 
Demographic and socioeconomic status was not considered influential in LAIV uptake 
for race, health insurance status, or family income. ACIP recommendations by age and 
year had the greatest impact on flu vaccine choice for this sample population. The results 
of this study can lead to social change by providing information for policy that can 
increase vaccine uptake, which can result in lower health cost and reduced illness and 
death rates associated with the flu, especially for those most at risk.  
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Section 1: Foundation of the Study and Literature Review  
Introduction 
In the United States, seasonal influenza outbreaks are associated with morbidity 
and mortality (Hull & Ambrose, 2011; Weycker et al., 2005; Wilson, Sanchez, 
Blackwell, Weinstein, & El Amin, 2013). The most effective method for preventing 
influenza and its complications is annual fall influenza vaccinations (Weycker et al., 
2005). Although annual influenza attack rates can be as high as 42% among school-age 
children (Carpenter et al., 2007), and children are most likely to transmit the illness to 
others, many children do not receive influenza vaccination. Increasing the number of 
children immunized against the flu also increases herd immunity by the indirect 
protection of household and community members (Lind et al., 2014). 
The live-attenuated influenza vaccine (LAIV) was developed to address issues 
associated with production and dissemination of the influenza vaccine for potential 
influenza pandemics and mass vaccination (Penttinen & Friede, 2016). Production of the 
inactivated influenza vaccine (IIV) takes time, and administering the vaccine requires 
basic safety and infection control measures due to its injectable nature. The LAIV option 
was ideal for mass vaccination of children, especially in a pandemic situation, due to its 
efficacy, production yield, availability for unanticipated serotypes, and user-friendly 
application (Penttinen & Friede, 2016). Roughly 30% of children vaccinated for the flu 
each year receive the LAIV, when available, whereas the other 70% receive the shot (IIV; 
Kahn, Santibanez, Zhai, & Singleton, 2015).  
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Annual surveillance and vaccine effectiveness research is conducted to improve 
influenza vaccines, anticipate seasonal virus strains, and track the circulation of influenza 
in the community (Kelly et al., 2009). Initial studies with comparisons of LAIV and IIV 
efficacy in young children indicated that LAIV is more effective than IIV for preventing 
the flu in children 2 to 8 years of age (Belshe et al., 2007). But subsequent studies have 
had conflicting results with the diminished effectiveness of the LAIV across all 
circulating influenza virus as opposed to IIV (Caspard et al., 2016; Eick-Cost et al., 2012; 
Flannery & Chung, 2016).  
The topic of this study is the relationship between the Advisory Committee on 
Immunization Practices (ACIP) flu vaccine recommendations, socioeconomic factors, 
demographic characteristics, and vaccine type among U.S. children. In addition to the 
reported inconsistencies in flu vaccine efficacy, annual influenza vaccine 
recommendations have varied in children 2 to 8 years of age. In 2016, data from four 
observational studies evaluating influenza vaccine effectiveness in the pediatric 
population during the 2015-2016 influenza season was presented to the ACIP (Flannery 
& Chung, 2016). The two studies conducted in the United States showed decreased 
effectiveness of LAIV compared to IIV (Grohskopf et al., 2016). However, studies in the 
United Kingdom and Finland showed the statistically significant efficacy of LAIV 
against all influenza strains ranging from 46% to 58%. These studies show LAIV and IIV 
effectiveness comparable to vaccine effectiveness in observational studies in prior 
seasons (Rhorer et al., 2009). Inconsistencies in vaccine recommendations impact 
vaccine uptake by diminishing the patients’ perceived benefits of following these vaccine 
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recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). For example, studies have 
shown that parents who delayed and refused vaccine doses were more likely to have 
vaccine safety concerns and perceive fewer benefits associated with these vaccines (Blyth 
et al., 2014; Cheney & John, 2013; Smith et al., 2011). 
This study is significant because the relationship between influenza vaccination 
recommendation by the ACIP and vaccine uptake among children is not known, leaving a 
gap in the literature. The potential positive social change and implications of this study 
include analysis of factors associated that could impact vaccine choice and help to 
improve vaccine recommendations and policies. The major sections of this chapter 
include the problem statement, study purpose, research question, theoretical foundation, 
nature of the study, literature review, and significance. The chapter will also include 
discussion of the assumptions, study scope, limitations, and significance of the study. 
Problem Statement  
The ACIP is a group of public health and medical and medical experts who 
develop recommendations on vaccine use among the civilian population of the United 
States for all children 6 months to 18 years of age before the annual influenza season 
(Hamborsky, Kroger, & Wolfe, 2015). There are two types of influenza vaccines 
available for children in the United States. These vaccines are either IIV (contains 
inactivated form of the virus) administered by shot or LAIV (contains a weakened form 
of the virus) a nasal mist (Flannery & Chung, 2016; Hamborsky, Kroger, & Wolfe, 2015; 
Kahn et al., 2015). The LAIV has increased in popularity since its introduction in 2003. 
For flu seasons 2011-2012, 2012-2013, and 2013-2014, over 30% of vaccinated children 
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received the LAIV (Kahn et al., 2015). In 2013 the ACIP recommended preference for 
LAIV, when available, for children 2 to 8 due to its efficacy compared to the IIV (Centers 
for Disease Control and Prevention [CDC], 2014). But the subsequent annual influenza 
efficacy research has indicated a reduction in LAIV efficacy against A/H1N1 in the 
United States (determined by a few test-negative, small sample size studies), resulting in 
ACIP no longer recommending the LAIV for any age group for the 2016-2017 flu 
season, though the LAIV vaccine will still be manufactured and available for use 
(Grohskopf et al., 2016).  
Discontinued recommendation of the LAIV by the ACIP because of reduced 
vaccine efficacy can reduce vaccination rates among children. According to Healthy 
People 2020, the ideal influenza vaccination rate of children is at least 70%, though each 
year actual vaccination rates fall short of the recommended threshold, ranging from 31.1 
to 59.3% of children ages 6 months to 17 years of age since 2007 (Peng-jun Lu et al., 
2013; Rose et al., 2014). Because the LAIV vaccine was recommended from the 2003-
2004 through the 2015-2016 flu seasons, little is known about the relationship between 
ACIP recommendations to discontinue LAIV recommendations and the impact of 
influenza vaccine uptake in the pediatric population.  
Purpose of the Study  
This study was conducted to evaluate the association between seasonal influenza 
vaccination ACIP recommendations, socioeconomic factors, demographic characteristics, 
and vaccine type among children over three consecutive flu seasons. LAIV was the 
recommended choice for children 2-8 during the 2014-2015 flu season, both LAIV and 
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IIV were equally recommended for the 2015-2016 flu season, and the LAIV 
recommendation was discontinued for the 2016-2017 season due to studies showing 
limited efficacy against A/H1N1 (Flannery & Chung, 2016). In addition, multiple 
socioeconomic and demographic factors can influence vaccine choice including age, race, 
family income, and health insurance status. The dependent variable for this study was 
influenza vaccine type (LAIV and IIV) among U.S. children. The independent variables 
were age, race, family income, health insurance status, and ACIP influenza vaccine 
recommendation by flu season (2014-2015, 2015-2016, and 2016-2017).  
Research Questions and Hypotheses 
Research Question 1: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season 
2014-2015?  
H01: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2014-2015. 
Ha1: There is a relationship between age, race, family income, health insurance 
status, vaccine type (LAIV/IIV) among U.S. children for flu season 2014-2015. 
Research Question 2: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season 
2015-2016?  
H02: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016.  
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Ha2: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016. 
Research Question 3: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/IIV) among U.S. children for flu season 
2016-2017?  
H03: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2016-2017.  
Ha3: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2016-2017. 
Research Question 4: What was the relationship between influenza vaccine type 
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 2014-
2015, 2015-2016, and 2016-2017? 
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV 
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred). 
Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016, 
and 2016-2017. 
Theoretical Foundation for the Study  
Social Ecological Model  
The use of ACIP recommendations, demographic characteristics, and 
socioeconomic status to evaluate influenza vaccine choice is guided by the social 
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ecological model. Although ACIP recommendations are not mandates, they may 
influence the availability of vaccines to consumers and their uptake in society. Once 
individuals have determined the need for the vaccine on a personal level, they look to 
public opinion and policy for guidance. 
The social ecological model identifies multiple factors that influence health 
behavior including the individual, interpersonal, institutional, community, and policy 
levels. The intrapersonal level is where health decisions are made based on personal 
beliefs and knowledge at the individual level. The interpersonal level is focused on social 
norms, influence in the community, and collective beliefs within a close social network 
(Kumar et al., 2012). This level consists of peers, general practitioners, family, and 
friends. The institutional level represents the health care system, medical institutions, and 
local health care practitioners. At the community level are media, health disparities, and 
social norms. For example, vaccine uptake increases as more people in the same 
community get vaccinated (Kumar et al., 2012). At the policy level is regulation, 
oversight, and governing recommendations.  
Variables at each level in the social ecological model are predictors of vaccine 
uptake (Kumar et al., 2012). In this case, patients have already made a choice to take the 
vaccine, so uptake was met at the intrapersonal level. For this study, the community and 
institutional levels of the social ecological model are represented by demographic and 
socioeconomic status. The policy level of the social ecological model is represented by 
ACIP recommendations. Although all levels affect vaccine uptake and choice, policies, 
socioeconomic and demographic factors can directly influence the other levels by altering 
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and influencing the access and desire of flu vaccinations. This is achieved by making 
certain vaccines unavailable, altering access, reducing their perceived effectiveness, 
limiting affordability, or indicating a belief of risk associated with their use. For example, 
the ACIP recommendation to discontinue use of LAIV for the 2016-2017 flu season can 
negatively influence influenza vaccine uptake. If the underlying cause of LAIV’s reduced 
efficacy is not defined and addressed due to conflicting policy and inconsistent 
recommendations by governing bodies, local health departments, and family 
practitioners, the public is left with limited or conflicting information to help guide 
vaccine choice.  
Nature of the Study 
This study was a quantitative cross-sectional study with secondary surveillance 
data provided by the CDC. The nature of this study is focused on ACIP recommendations 
and socioeconomic status and demographic characteristics regarding how they translate 
to vaccine choice among children residing in the United States. Secondary publicly 
available data were used to evaluate vaccine uptake by type among children over three 
recent flu seasons (2014-2015, 2015-2016, and 2016-2017) with different children 
sampled each year.  
The key study variables include vaccine uptake of LAIV or IIV among U.S. 
children over three consecutive flu seasons with differing ACIP recommendations in 
addition to demographic and socioeconomic status defined as age, race, family income, 
and health insurance. The population for this study includes children (0 to 17 years of 
age) over three consecutive flu seasons (2014-2015, 2015-2016, and 2016-2017). The 
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sample population for influenza vaccinations is provided by the National Health 
Interview Survey (NHIS). The NHIS is a cross-sectional household interview survey 
conducted continuously throughout each year. Data are collected by the U.S. Census 
Bureau employees through a personal household interview consisting of four major 
components: household, family, sample adult, and sample child. 
Literature Search Strategy 
A search of relevant literature was done in the following databases: 
ScienceDirect, Google Scholar, Walden Library, and NIH. Search terms included live-
attenuated influenza vaccine, LAIV, vaccine effectiveness, vaccine efficacy, LAIV, ACIP 
flu, health belief model vaccinations, child influenza, and influenza vaccine. Peer-
reviewed articles and CDC reports were chosen to provide the most recent information. 
Articles focused on side effects or risk associated with the flu vaccine were excluded 
because they did not relate to the study topic. This initial literature search identified 
around 87 documents for further review and analysis.  
Literature Review  
Influenza is primarily transmitted from person to person via airborne-infected 
droplets that are disseminated when an infected person sneezes or coughs. These infected 
droplets can be transferred to susceptible persons within 3 feet of the infected individual. 
Transmission can also occur through direct or indirect contact with contaminated surfaces 
(Hamborsky et al., 2015). Humans are currently the only reservoir of influenza types B 
and C, although influenza A viruses infect both humans and animals (Hamborsky et al., 
2015). Influenza activity generally peaks from December to March in temperate climates 
10 
 
and occurs throughout the year in tropical regions (Deyle, Maher, Hernandez, Basu, & 
Sugihara, 2016). Adults can transmit influenza for 6 days from 1 day before symptoms 
appear to the first 5 days of the illness, and children can spread influenza for 10 or more 
days (Hamborsky et al., 2015). Once infected, the influenza virus penetrates respiratory 
epithelial cells where replication occurs resulting in the destruction of the host cell 
(Hamborsky et al., 2015) 
The flu is rapidly transmitted in large populations with close contact, especially in 
the fall and winter months during the traditional academic school year. Seasonal 
influenza is estimated to impact 10 to 20% of the United States population annually (Hull 
& Ambrose, 2011). School-age children have the highest influenza transmission and 
infection rate, ranging from a 10 to 40% attack rate yearly (Wilson et al., 2013). 
Additionally, according to the CDC (2016), pediatric mortality is highest between 5 and 
11 years of age, especially when combined with a secondary bacterial infection. Further, 
annual influenza attack rates among school-age children, who transmit the infection to 
others, can be as high as 42% (Carpenter et al., 2007). However, annual fall influenza 
vaccinations are the most effective method for preventing influenza and its complications 
(Weycker et al., 2005). The vaccination of children has been shown to reduce the impact 
of influenza on the communities where they reside, which is important for at-risk 
populations such as those 65 years of age and older (Wilson et al., 2013). Thus, the 
World Health Organization recommends a seasonal flu vaccination consisting of a 75% 
coverage rate for high-risk populations (Longini & Halloran, 2005). 
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Influenza Vaccine and Advisory Committee on Immunization Practices 
Recommendations  
There are two types of influenza vaccine available for children in the United 
States. These vaccines are either IIV (administered by shot) or LAIV (a nasal mist) and 
contain influenza type A(H1N1), type A(H3N2), and type B (Caspard et al., 2016; 
Hamborsky et al., 2015). The LAIV has increased in popularity since its introduction in 
2003. For flu seasons 2011-2012, 2012-2013, and 2013-2014 over 30% of vaccinated 
children received the LAIV (Kahn et al., 2015). In 2013 the ACIP recommended 
preference for LAIV, when available, for children 2 through 8 due to its vaccine efficacy 
compared to the IIV (CDC, 2014). Subsequent annual influenza efficacy research has 
indicated a reduction in LAIV potency against A/H1N1 in the United States, resulting in 
ACIP no longer recommending the LAIV for any age group for the 2016-2017 flu season 
(Robinson, 2016). 
The ACIP recommends influenza vaccination for all children 6 months to 18 
years of age before the annual influenza season. The CDC identified the average flu 
season beginning in October each year and extending through March of the following 
year (Peng-jun Lu et al., 2013). Due to the inconsistent nature of the annual flu season 
and vaccine uptake, data will be aggregated by month to include 6 months of each year 
for a total of 12 months. Therefore, the 2014-2015 season was from July 1, 2014, to June 
31, 2015, flu season 2015-2016 from July 1, 2015, to June 31, 2016, and season 2016-
2017 include July 1, 2016, to June 31, 2017. 
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Inactivated Influenza Vaccine (IIV)  
Influenza vaccination only provides temporary immunity due to antigenic drift 
which contributes to seasonal outbreaks of the flu virus. For the IIV influenza conferred 
immunity is less than a year and depends on the individual and circulating flu strains 
(Hamborsky et al., 2015). Studies show influenza vaccines are effective in protecting 
about 60 % of healthy people under age 65 years when seasonal strains are closely 
matched (Tricco et al., 2013). The Influenza vaccine is less effective in populations over 
65 years old in preventing illness but may reduce the duration and severity of the illness 
resulting in reduced influenza-related hospitalization and death (Hamborsky et al., 2015).  
Live-Attenuated Influenza Vaccines (LAIV) 
LAIV was approved in the United States in 2003. The LAIV and IIV contain the 
same influenza viruses each season as determined by the World Health Organization 
annually. LAIV contains cold-adapted, weakened influenza viruses that confer immunity 
by replication in the nasopharynx (Lanthier et al., 2011). Rather than an injection used for 
IIV, the LAIV is administered from a single-dose sprayer unit, half of the dose is sprayed 
into each nostril (MedImmune, 2016). LAIV is approved for use in healthy patients from 
2 to 49 years of age (Hamborsky et al., 2015). 
Varied Seasonal Efficacy  
How well the flu vaccine work depends on multiple factors and can change 
seasonally. Significant factors contributing to vaccine effectiveness are characteristics of 
the individuals being vaccinated like age, health status, and time of vaccination during 
the flu season (Rhorer et al., 2009). In addition, the viruses chosen for the vaccine are 
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most effective when they are similar to the circulating flu viruses in the community 
(CDC, 2014). Due to these variables determining influenza effectiveness is challenging 
and requires annual evaluation to determine the most effective means of protecting the 
population from the flu virus.  
Hemagglutinin and neuraminidase are surface antigens located on the influenza 
virus that can be identified by the immune system if previous exposure has produced the 
correct antigens (Rhorer et al., 2009; Sultana et al., 2014). The influenza virus alters these 
surface proteins to escape detection in the host resulting in an illness called antigenic 
drift. Antigenic drift is a minimal alteration in surface antigens where antibodies from 
exposure to previous similar strains may provide partial immunity (Hamborsky et al., 
2015). Antigenic shift also results in host illness when two influenza viruses share genetic 
information to produce a new influenza strain unknown to the host immune system. 
Antigenic shift tends to be more virulent in the population because the virus is completely 
unknown to the immune system (Hamborsky et al., 2015). Table 1 shows vaccine 
effectiveness estimates from 2014-2017 (Chung et al., 2016; Flannery & Chung, 2016; 
Flannery et al., 2017).  
Table 1 
 
U.S. Flu Vaccine Effectiveness Estimates for 2014-2017 
     2014-2015 2015-2016 2016-2017 
 
Age 
Adjusted 
VE % 
 
95% CI 
Adjusted 
VE % 
 
95% CI 
Adjusted 
VE % 
 
95% CI 
6 mo-8 yr 25 (6 to 40) 48 (31 to 61) 61 (49 to 70) 
9-17 25 (2 to 42) 64 (44 to 77) 35 (13 to 61) 
Note. VE = vaccine efficacy. Adjusted for age, sex, race/ethnicity, self-rated general 
health status, days from illness onset to enrollment, and calendar time of illness onset. 
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Discontinued Live-Attenuated Vaccine and Advisory Committee on Immunization 
Practices Recommendations  
Vaccine recommendations in the United States are developed annually by the 
Advisory Committee on Immunization Practices. An intranasal cold-adapted, LAIV was 
first approved for use in the United States in 2003 (Rose et al., 2014). In September 2007, 
the U.S. Food and Drug Administration expanded the indication for use in individuals 2 
to 49 years of age, from the previous 5 to 49 years of age indication (Hamborsky et al., 
2015).  
In June 2016, data from four observational studies evaluating influenza vaccine 
effectiveness in the pediatric population during the 2015-2016 influenza season was 
presented to the ACIP (Flannery & Chung, 2016). The two studies conducted in the U.S. 
showed decreased effectiveness of LAIV compared to IIV (Grohskopf et al., 2016). For 
the 2015-2016 U.S. flu season the Influenza Vaccine Effectiveness Network “showed no 
significant vaccine effectiveness among children aged 2 through 17 years for LAIV for 
all influenza A and B viruses combined (3%; 95% CI = -49–37) or for influenza 
A(H1N1) (-21%; 95% CI = -108–30)”(Grohskopf et al., 2016), Studies carried out by 
MedImmune (LAIV manufacturer), the United Kingdom (35%; 95% CI: -29.9 to 67.5), 
and Finland (51%; 95% CI: 28 to 66%) showed the statistically significant efficacy of 
LAIV against all influenza strains (Matrajt, Halloran, & Antia, 2018). These studies 
showed LAIV and IIV effectiveness comparable to vaccine effectiveness observational 
studies in prior seasons. 
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Herd Immunity and Children  
Increasing the number of children immunized against the flu also increases herd 
immunity defined by the indirect protection of household and community members that 
are unable to receive the vaccine, or that may be at high risk for adverse flu-related 
outcomes (Lind et al., 2014). Children tend to experience higher attack rates of annual 
influenza than other populations and gain more complete protection from flu vaccinations 
making them the ideal target population to slow transmission in the community or reduce 
incidence among population segments that may be at risk of severe consequences of 
infection (Fine, Eames, & Heymann, 2011).  
High vaccination coverage reduces exposure of unvaccinated persons to infection, 
resulting in indirect protection in addition to direct protection for the those vaccinated 
(Glezen, Gaglani, Kozinetz, & Piedra, 2010). The direct effect of immunity reduces 
infection rates among vaccinated individuals resulting in less infection circulating in the 
community, less influenza exposure, resulting in herd immunity by indirect means (Fine 
et al., 2011). Increasing the number of school-age children immunized against the flu also 
increases herd immunity by the indirect protection of household and community 
members (Lind et al., 2014). 
Uptake in the Community  
Annual surveillance and vaccine effectiveness research are conducted to improve 
influenza vaccines, anticipate seasonal virus strains, and track the circulation of the of 
influenza in the community (Kelly et al., 2009). Previous clinical trials of LAIV in young 
children have shown it to be highly effective (Belshe et al., 2007). Initial studies 
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comparing LAIV and IIV efficacy in young children found LAIV to be more effective in 
preventing the flu in children 2-8 years of age. Subsequent studies have had conflicting 
results with the diminished effectiveness of the LAIV across all circulation influenza 
virus as opposed to IIV.  
Over half of all flu vaccines in the U.S. are administered to individuals ages 6 
months to 17 years old (Peng-jun Lu et al., 2013). Studies addressing flu vaccination 
barriers cite time off work, cost, and lack of convenience as determining factors in 
vaccinating school children for the flu. According to the Morbidity and Mortality Weekly 
Report, the United States vaccination coverage is consistently below the Healthy People 
2020 goal of 70 % (Peng-jun Lu et al., 2013). 
In addition to the reported inconsistencies in flu vaccine efficacy, annual 
influenza immunization recommendations have varied in children 2-8 years of age. 
Inconsistencies in vaccine recommendations can negatively impact vaccine uptake in the 
community by diminishing the patients perceived benefits of following vaccine 
recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). Studies show parents who 
delayed and refused vaccine doses were more likely to have vaccine safety concerns and 
perceive fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney & 
John, 2013; Smith et al., 2011). 
Socioeconomic and Demographic Factors  
Socioeconomic and demographic factors have the potential to influence the 
outcome of a study by an indication of a relationship among variables where one does not 
truly exist. For this study, four variables have been identified as factors that may 
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influence vaccine uptake and choice among children in the United States population. 
These factors include age, race, family income, and health insurance status.  
Age. Age has been identified as a factor that may influence vaccine uptake due to 
ACIP recommendations. The ACIP recommends influenza vaccination for all children 6 
months to 18 years of age before the annual influenza season. While LAIV was approved 
by the FDA for use in healthy patients from 2 to 49 years of age for previous seasons, 
ACIP recommendations focused on children ages 2-8 years of age (Hamborsky et al., 
2015).  
Race. Race has been identified as a factor that may also influence vaccine update 
due to disparities in vaccine uptake among minorities in the United States. According to 
Chen (2007), flu vaccine rates among five ethnic groups (White, Latino, African 
American, Filipino American, and Japanese American) varied significantly. Among all 
participants who indicated they were concerned about getting the flu, individuals 
identified as White or African American were more likely to get vaccinated than Latino 
Americans (Chen, Fox, Cantrell, Stockdale, & Kagawa-Singer, 2007). Latino American 
were more likely to report access and cost as flu vaccination barriers, and African 
Americans noted concerns regarding the safety of flu vaccines.  
Family income. Family income has been identified as another factor that may 
also influence vaccine update due to the time and cost associated with vaccination. A 
study by Cohen (2012), noted more than 10 % of those who were not vaccinated reported 
prohibitive cost as a reason. Another study indicated low pediatric influenza vaccination-
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acceptance rates of 40.8 % in family’s whose income was $40,000 or less annually 
(Frew, Hixson, Rio, Esteves-Jaramillo, & Omer, 2011).  
Health insurance status. Health insurance status has been identified as a 
covariate due to its potential influence on cost and access barriers associated with 
vaccination. According to Frew (2011), “children with private insurance were more likely 
to be up-to-date with immunizations compared with those with public insurance or no 
insurance although parents without health insurance indicated that they were more likely 
to vaccinate their children against H1N1 than parents with health insurance.” 
Definitions 
Dependent Variable:  Childhood influenza vaccination by type (LAIV or IIV) 
Independent Variables: ACIP recommendations by flu seasons (2014-2015, 2015-
2016, and 2016-2017). Socioeconomic and demographic factors that may contribute to 
influenza vaccine type including; age, race, family income, and insurance status. 
Advisory Committee on Immunization Practices (ACIP): A group of medical and 
public health experts that develop recommendations annual influenza vaccination for all 
persons 6 months of age and older in the United States (Harris et al., 2014). 
Attack Rate: is the cumulative incidence of influenza virus infections in a defined 
population (Jayasundara, Soobiah, Thommes, Tricco, & Chit, 2014).  
Assumptions 
The following assumptions are made about this study: 
• The study sample is representative of the population.  
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• Secondary information provided by the CDC and WHO is accurate and 
timely.  
• Parent-administered surveys about their child’s influenza vaccination status 
are accurate.  
These assumptions are made because the data used for this study is secondary and 
deviation from these factors cannot be controlled for through study design or primary 
sampling.  
Scope and Delimitations 
The focus of this study is influenza vaccination rates of children ages 0 to 17 
years of age in the United States; CDC reports for 2014-2015, 2015-2016, and 2016-2017 
flu seasons. Studies show vaccination uptake (yes/no) varies among individuals based on 
socioeconomic and demographic factors (Chen et al., 2007; Frew et al., 2011; Galarce, 
Minsky, & Viswanath, 2011; Hamborsky et al., 2015). These factors will be evaluated as 
they may also contribute to flu vaccine uptake by type (IIV/LAIV) in the community. 
Socioeconomic and demographic status for this study included age, race, family income, 
and health insurance status.  
The delimitations of this study are:  
• Three influenza seasons; 2014-2015, 2015-2016, and 2016-2017  
• quantitative cross-sectional study  
• Including US population  
• Includes vaccination rates of children ages 0-17 years old.  
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An issue of generalization may occur because the secondary data set uses limited 
variables to define race among participants, where race identification is complex and may 
not be consistent throughout the U.S. population.  
Significance 
The potential contribution of this study is to add to current knowledge regarding 
influenza recommendations and influenza vaccine uptake among children. Most flu 
vaccine research evaluates the efficacy of the vaccine based on a test-negative design (a 
variation of the case-control design). Few studies evaluate influenza vaccine uptake by 
type socioeconomic status, demographic characteristics, and ACIP recommendations. 
This study aims to assess how socioeconomic and demographic status impacts vaccine 
uptake for three consecutive flu seasons and how ACIP recommendations influence 
LAIV uptake among children in the United States over the three most recent flu seasons.  
Vaccination uptake is significantly influenced by social and psychological factors, 
some of which are under-reported and poorly understood (Wheelock, Miraldo, Parand, 
Vincent, & Sevdalis, 2014). Although structural barriers are known to limit vaccination 
rates, social and psychological factors may also affect the decision to vaccinate children. 
Perceptions about flu susceptibility and vaccine effectiveness significantly influence 
vaccination adoption (Wheelock et al., 2014). Evaluating current procedures and policies 
could improve patient perceptions and access.  
Policies can directly influence the other levels by altering and influencing the 
access and desire of flu vaccinations by making them unavailable, altering access, 
reducing their perceived effectiveness, limiting affordability, or indicating belief of risk 
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associated with their use. The discontinued ACIP recommendation of the LAIV has the 
potential to negatively influence influenza vaccine uptake in general if the underlying 
cause of LAIV’s reduced efficacy is not defined and addressed due to conflicting policy, 
and inconsistent recommendations by governing bodies, local health departments, and 
family practitioners. Improving vaccine recommendations and policy may lead to 
increased vaccine uptake and result in fewer sick days, reduced suffering, increased 
productivity, lower health cost and reduced illness and death associated with the flu virus 
especially for those most at risk.  
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Section 2: Research Design and Data Collection 
Introduction 
The purpose of this study was to examine the relationship between seasonal 
influenza vaccination ACIP recommendations, socioeconomic status, demographic 
characteristics, and vaccine uptake among children over three consecutive flu seasons. 
The dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children. 
The independent variables were ACIP influenza vaccine recommendation by flu season 
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomic-
demographic status indicated by age, race, family income, and health insurance status. 
The major sections of this chapter include research design, methodology, and threats to 
validity. The chapter will also include discussion of the study population, sampling, 
operational constructs, and ethical procedures.  
Research Design and Rationale 
This quantitative cross-sectional study included the NHIS secondary data reported 
by the CDC for flu seasons 2014-2015, 2015-2016, and 2016-2017 to evaluate the 
relationship between childhood influenza vaccination rates, ACIP recommendations, 
socioeconomic factors, and demographic characteristics. This study design allowed for 
timely analysis of a large dataset and is commonly used to assess policies and their 
impact on community health. This type of analysis is also used to examine the 
relationship between exposure and outcome prevalence in a defined population at a single 
point in time (Oleckno, 2002). The cross-sectional research design also provided 
advantages in being quick and easy to conduct because the data on selected variables are 
23 
 
only collected once. Multiple exposures and outcomes can be measured simultaneously, 
resulting in the ability to measure prevalence for all variables being studied in a specific 
population (Oleckno, 2002).  
Methodology  
Population 
The population for this study includes children residing in the United States over 
three consecutive flu seasons including 2014-2015, 2015-2016, and 2016-2017. The 
sample population for influenza vaccinations is provided by the NHIS. The NHIS survey 
is conducted from October through June each year for children 0 to 17 years of age. 
NHIS data are used to assess annual flu vaccination coverage by age at the national, state, 
and selected local levels and estimates are based on the parent or guardian reported data 
(CDC, 2017). Table 2 describes the variables used in this study. 
Table 2 
 
Study Variables 
Variables Description Inclusion criteria Variable type 
Dependent Flu vaccine status  LAIV, IIV Nominal/Categorical   
Independent ACIP 
recommendation  
Flu seasons 2014-2015, 2015-
2016, and 2016-2017 
Nominal/Categorical   
 Age Under a year old to 17 years of 
age 
Nominal/Categorical   
 Race White, Black, Hispanic, Asian, 
Other 
Nominal/Categorical  
 Family income $0 - $34,999, $35,000 - 
$74,999, $75,000 - $99,999, 
$100,000 and over 
Nominal/ 
Categorical/Ordinal   
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 Health insurance 
status  
Private, Medicaid and other 
public, other coverage, 
uninsured  
 
Nominal/Categorical   
 Year  2014-2015, 2015-2016, 2016-
2017  
Nominal/Categorical   
 
Sampling and Sampling Procedures 
Secondary surveillance data provided by the CDC were used in this study based 
on the NHIS, which is a cross-sectional household interview survey targeting the civilian 
noninstitutionalized population in the United States (CDC, 2018). The NHIS is conducted 
as a face-to-face interview, stratified by each U.S. state and the District of Columbia 
(CDC, 2018). Data are collected continuously throughout the year by The U.C. Census 
interviewers. The NHIS is conducted using computer-assisted personal interviewing, 
which guides the interviewer through the questionnaire where the interviewer enters 
responses into the computer (CDC, 2018). Subsequent survey questions are based on 
answers to previous questions, and the responses data is automatically saved in the survey 
data file (CDC, 2018). 
For each household with children, a sample adult 18 and over and a sample child 
under the age of 17 are randomly chosen to participate in the survey (CDC, 2018). In 
addition, the NHIS sample design oversamples non-White individuals to make sure all 
races are represented in the study. Information about the sample child is acquired from an 
adult residing in the household who is knowledgeable about the child’s health (CDC, 
2018). 
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All individual identifying information collected by the NHIS is held confidential 
and such information is not disclosed or released to anyone for any other purpose without 
the consent of the respondent (CDC, 2018). The National Center for Health Statistics 
must adhere to Section 308(d) of the Public Health Service Act (42 U.S.C. 242m) and the 
Confidential Information Protection and Statistical Efficiency Act (44 U.S.C. 3501 note) 
to protect the privacy of participants (National Center for Health Statistics, 2015b, 2016b, 
2017b). 
Sample Size  
According to the NHIS, the sample size can vary from year to year. The publicly 
released NHIS data files for 2015 contain data for 41,493 households, including 42,288 
families, 103,789 persons, and 12,291 children (National Center for Health Statistics, 
2015b). Additionally, according to the National Center for Health Statistics,  
The 2015 conditional response rate for the Sample Child component was 91.4 %, 
which was calculated by dividing the number of completed Sample Child 
interviews (12,291) by the total number of eligible sample children (13,444). The 
unconditional or final response rate of 63.4 % for the Sample Child segment was 
calculated by multiplying the conditional rate of 91.4 % by the final family 
response rate of 69.3 % (National Center for Health Statistics, 2015a, p.16). 
Of the 12,291 children surveyed for the 2014-2015 flu season, 5,847 (47.57 %) were 
vaccinated for the flu (National Center for Health Statistics, 2015a). According to NHIS 
data, 4,252 (74.79%) received the shot, and 1,369 (24.08%) received the nasal mist 
(National Center for Health Statistics, 2015a).  
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The publicly released data files for the 2016 NHIS contain data for 40,220 
households containing 40,875 families, 97,169 persons, and 11,107 children (National 
Center for Health Statistics, 2016b). Additionally,  
The conditional response rate for the Sample Child component was 92.3 %. The 
unconditional or final response rate of 61.9 %, for the Sample Child segment, was 
calculated by multiplying the conditional rate of 92.3 % by the final family 
response rate of 67.1 %. (National Center for Health Statistics, 2016b, p. 15). 
Of the 11,107 children surveyed for the 2015-2016 flu season, 5,299 (47.70%) were 
vaccinated for the flu (National Center for Health Statistics, 2016b). According to NHIS 
data, 4,099 (78.90%) received the shot, and 1,038 (19.98%) received the nasal mist 
(National Center for Health Statistics, 2016b). 
The publicly released data files for the 2017 NHIS contain data for 32,617 
households containing 33,157 families, 78,543 persons, and 8,845 children (National 
Center for Health Statistics, 2017b). Further,  
The conditional response rate for the Sample Child component was 92.1 %, which 
was calculated by dividing the number of completed Sample Child interviews 
(8,845) by the total number of eligible sample children (9,601). The unconditional 
or final response rate of 60.6 % for the Sample Child segment was calculated by 
multiplying the conditional rate of 92.1% by the final family response rate of 
65.7% (National Center for Health Statistics, 2017b, p. 15). 
Of the 8,845 children surveyed for the 2016-2017 flu season, 4,024 (45.49 %) were 
vaccinated for the flu (National Center for Health Statistics, 2017b). According to NHIS 
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data, 3571 (91.24%) received the shot, and 293 (7.49%) received the nasal mist (National 
Center for Health Statistics, 2017b).  
The sample for this study includes 13,347 children ages 0-17 residing in the 
United States. These cases were chosen based on the data provided; children who did not 
receive the flu vaccine were excluded from the sample. Additional cases that did not have 
responses for all independent variables were also excluded.  
Instrumentation and Operationalization of Constructs 
The NHIS data are used to examine annual influenza coverage of children ages 0 
to 17 years of age. Data used for this study are provided by the CDC, are open use, and 
include all study variables (National Center for Health Statistics, 2015a, 2016a, 2017a).  
Study Variables  
Dependent variable. The dependent variable was influenza vaccination type 
among children ages 0-17 years of age for each flu season, where IIV is coded as 1, and 
LAIV coded as 2. Table 3 includes description and coding for the dependent variables.  
Table 3 
 
Dependent Variable Descriptions 
Variable name  Description and coding Variable type Study code 
CSHSPFL1 
2014-2015  
Was this a shot, or was it a 
vaccine sprayed in the nose? 
nominal 0 Flu shot  
1 Flu nasal spray or 
“LAIV.”  
 
CSHSPFL1 
2015-2016 
Was this a shot, or was it a 
vaccine sprayed in the nose? 
nominal 0 Flu shot  
1 Flu nasal spray or 
“LAIV.”  
 
CSHSPFL1 
2016-2017  
Was this a shot, or was it a 
vaccine sprayed in the nose? 
nominal 0 Flu shot  
1 Flu nasal spray or 
“LAIV.”  
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Note. Data Source: NHIS, 2015, 2016, and 2017. Exclude CSHSPFL1 (7 = Refused, 8 = 
Not ascertained, and 9 = Don’t know) 
 
Independent variables. Independent variables include year (Research Question 4 
only), age, race, family income, and health insurance status (Research Questions 1-3 
only). Age was recoded into categorical variables to include children younger than 1 year 
of age in the analysis. Table 4 includes description and coding for the independent 
variables. 
Table 4 
 
Independent Variable Descriptions  
Note. Data Source: NHIS, 2015, 2016, and 2017. 
Variable Description and coding Variable type Study code 
AGE_P 
(Research 
Question 1-3) 
Age  Nominal  (1) 0-2 
(2) 3-5 
(3) 6-8 
(4) 9-11 
(5) 12-14 
(6) 15-17 
 
HISCODI3 
(Research 
Question 1-3) 
Race  Nominal  (1) Hispanic 
(2) White 
(3) Black 
(4) Asian 
(5) All other race groups 
 
INCGRP5 
(Research 
Question 1-3) 
Total combined family 
income (grouped) 
Nominal  (1) $0 -$34,999 
(2) $35,000 - $74,999 
(3) $75,000 - $99,999 
(4) $100,000 and over 
 
COVER 
(Research 
Question 1-3) 
Health insurance 
coverage 
Nominal  (1) Private 
(2) Medicaid and other public 
(3) Other coverage 
(4) Uninsured 
 
YEAR 
(Research 
Question 4) 
Data year  Nominal  (1) 2015  
(2) 2016 
(3) 2017  
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Data Analysis Plan 
IBM SPSS Statistics version 24 and SAS student edition software packages were 
used for the statistical analysis of this study. Binary logistic regression was employed to 
explore the relationship between influenza vaccination type, age, race, family income, 
and health care status for Research Questions 1-3. Data from three consecutive flu 
seasons were combined for Research Question 4; cases with missing variables were 
excluded. Calculations include descriptive statistics on the tested association between 
ACIP recommendations, vaccine type, and socioeconomic-demographic status. Data for 
all three consecutive flu seasons were publicly reported by the CDC. The influenza 
season time periods are based on historical data provided by the CDC.  
Analysis Plan for Each Research Question  
Research Question 1: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2014-2015?  
H01: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-
2015. 
Ha1: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-
2015. 
The independent variables were age, race, family income, and health insurance 
status. The dependent variables were vaccine type (LAIV/IIV) for this research question. 
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These variables are part of the NIS secondary data set provided by the CDC. Descriptive 
will be utilized to identify outliers and distribution. Binary logistic regression analysis 
between socioeconomic-demographic status and flu vaccine type for flu season 2014-
2015 will be used to test this hypothesis. A P-value < 0.05 indicates rejection of the null 
hypothesis.  
Research Question 2: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2015-2016?  
H02: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-
2016.  
Ha2: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-
2016. 
The independent variables were age, race, family income, and health insurance 
status. The dependent variables were vaccine type (LAIV/IIV) for this research question. 
These variables are part of the NIS secondary data set provided by the CDC. Descriptive 
will be utilized to identify outliers and distribution. Binary logistic regression analysis 
between socioeconomic status, demographic characteristics, and flu vaccine type for flu 
season 2015-2016 will be used to test this hypothesis. A P-value < 0.05 indicates 
rejection of the null hypothesis. 
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Research Question 3: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2016-2017?  
H03: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-
2017.  
Ha3: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-
2017. 
The independent variables were age, race, family income, and health insurance 
status. The dependent variables were vaccine type (LAIV/IIV) for this research question. 
These variables are part of the NHIS secondary data set provided by the CDC. 
Descriptive will be utilized to identify outliers and distribution. Binary logistic regression 
analysis between socioeconomic status, demographic characteristics, and flu vaccine type 
for flu season 2016-2017 will be used to test this hypothesis. A P-value < 0.05 indicates 
rejection of the null hypothesis. 
Research Question 4: What is the relationship between influenza vaccine type 
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 2014-
2015, 2015-2016, and 2016-2017?  
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV 
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).  
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Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-
2016, and 2016-2017. 
The independent variable is ACIP recommendations, and the dependent variable 
is vaccine type. These variables are part of the NHIS secondary data set provided by the 
CDC. The chi-square test of homogeneity will be used to determine if a difference exists 
between the binomial proportions of three independent groups (flu season) on a 
dichotomous dependent variable (vaccine type). This test will be used to determine 
whether the proportions are statistically significant between groups indicated by flu 
season. A P-value < 0.05 indicates rejection of the null hypothesis. If there are 
statistically significant differences in proportions, a post hoc test will determine how 
these groups differ. 
Threats to Validity 
Content validity is defined by the inclusion of all the characteristics of the 
construct being measured (Frankfort-Nachmias & Nachmias, 2008). Type I sampling 
error is a false positive while a type II sampling error is a false negative result in 
hypothesis testing (Oleckno, 2002). Therefore, a type I error detects an association that is 
not present, and a type II error is failing to identify a positive relationship. Type I 
sampling error is measured by the p-value; a high p-value indicates a potential sampling 
error resulting in a false association. P values less than 0.05 are statistically significant 
and determined by the alpha level (Blair & Taylor, 2008). A substantial sample size 
increases the chance for statistical significance. Type II sampling error is measured by the 
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beta level. The smaller the beta level, the higher the statistical power. The beta level is 
also affected by the sample size, the larger the sample, the less likely for a type II error. 
Confidence intervals that are narrow suggest the associations are precise (Blair & Taylor, 
2008). The survey data for this study provides a large sample size and reduces the risk of 
Type I or II error.  
Reliability is determined by a measurements ability to provide similar results in 
subsequent tests, calculation of standard deviation can account for the variance in 
collected data. Standard deviation is used for quantifying the dispersion of a set of data 
values (Oleckno, 2002). Test results will vary from person to person falling within a bell 
cover with most cases located near the mean. A small standard deviation indicates that 
the data points tend to be close to the mean, reflecting increased reliability (Blair & 
Taylor, 2008). A high standard deviation indicates a lack of consistency with results 
spread out over a wide range of values. The standard deviation is also used to measure 
confidence in the statistical conclusions of a study and provide the likelihood of values 
falling within the same range if the same study is repeated (Blair & Taylor, 2008). 
Confidence intervals will be reported in the final analysis to show the reliability of study 
results. 
An issue of generalization may occur because the secondary data set uses limited 
variables to define race among participants, where race identification is complex and may 
not be consistent throughout the U.S. population. Other factors may influence vaccine 
uptake beyond those in the scope of this study resulting in a potential type I or II error.  
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The Strengths and Limitations of these Measurements  
Cross-sectional quantitative research investigates the relationship between 
variables in their natural environment rather than a laboratory setting (Polit & Hungler, 
1999). This type of investigation often utilizes data from descriptive studies to formulate 
hypotheses, determine a relationship between variables, and test theories. A Cross-
sectional study evaluates the nature of relationships that exist and does not infer causality, 
like traditional experimental studies (Creswell, 2012). 
The data from the NHIS survey is cross-sectional, based on an annual sample 
representing a changing cohort of subjects (CDC, 2015). In this case, the NHIS does not 
collect information from all subgroup populations omitting institutionalized individuals 
including military families. This data is secondary, so the health information collected 
does not include verifiable medical data or laboratory data (Rolnick et al., 2013). Some 
survey respondents may not be forthcoming about a behavior many consider to be 
undesirable. It is important to take into account the limitations inherent in self-reported 
data, including but not limited to reembrace error, reporting bias, incorrect 
documentation, and loss of cases. 
One of the greatest limits to measuring a relationship among variables is the 
assumption of generalizability (Creswell, 2012). While statistical analysis of data sets 
may reveal that two variables tend to vary together, it does not mean they actually do. If 
the data is not representative of the real population, study results could indicate a 
relationship among variables that does not truly exist in the actual population. There are a 
number of unknown factors called confounders that can be unaccounted for resulting in a 
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false perception of a relationship among variables (Oleckno, 2002). In this study, 
potential confounders will be evaluated to try and control for these factors. Other 
unknown factors could also contribute to confounding but are not addressed in this study.  
Ethical Procedures 
No ethical issues were identified in this study. None of the individuals surveyed 
are identified in the data provided by the CDC. According to the CDC (2017), 
“Information collected in the National Immunization Surveys is used only for reporting 
important statistical information about health issues.” By law sensitive information like 
name, address or telephone number about any specific individual are not publicly 
available, and the CDC abides by these regulations. No efforts will be used to identify 
cases, only public use data will be used for this study, and all data will be kept on a 
password protected computer not shared on a network. Institutional review board (IRB) 
approval will be obtained prior data analysis to confirm that patient privacy is protected.  
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Section 3: Presentation of the Results and Findings 
Introduction 
The purpose of this study was to examine the relationship between seasonal 
influenza vaccination ACIP recommendations, socioeconomic status, demographic 
characteristics, and vaccine uptake among children over three consecutive flu seasons. 
The dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children. 
The independent variables were ACIP influenza vaccine recommendation by flu season 
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomic-
demographic status indicated by age, race, family income, and health insurance status. 
Research Question 1: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2014-2015?  
H01: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015. 
Ha1: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015 
Research Question 2: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2015-2016?  
H02: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016.  
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Ha2: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016. 
Research Question 3: What is the relationship between age, race, family income, 
health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 
2016-2017?  
H03: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017.  
Ha3: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017. 
Research Question 4: What is the relationship between influenza vaccine type 
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 2014-
2015, 2015-2016, and 2016-2017?  
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV 
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).  
Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016, 
and 2016-2017. 
The major sections of this chapter include data collection and the results of the 
study. The chapter will also include frequencies, population representation, hypothesis 
analysis, and a summary of the findings. 
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Data Collection and Secondary Dataset  
Vaccination rates are documented annually by the CDC, which also involved the 
ACIP, a group of public health and medical experts who make vaccine recommendations 
updated annually to reflect continued research and development (Harris et al., 2014). The 
CDC uses multiple methods to document and surveys vaccination rates for vaccines 
recommended by the ACIP. In this cross-sectional study, secondary surveillance data 
provided by the CDC, from the NHIS, were used. The NHIS is a cross-sectional 
household interview survey targeting the civilian noninstitutionalized population residing 
in the United States (CDC, 2018). The NHIS is conducted as a face-to-face interview, 
stratified by each U.S. state and the District of Columbia (CDC, 2018). The U.S. Census 
Bureau is the data collection agency for the NHIS, and data are collected continuously 
throughout the year by census interviewers. According to the National Health Survey,  
The sampling plan follows a multistage area probability design of clusters of 
addresses that are located in primary sampling units (PSU’s). A PSU consists of a 
county, a small group of contiguous counties, or a metropolitan statistical area. 
The NHIS sample is divided into four separate panels, so each panel is a 
representative sample of the U.S. population. This design feature has a number of 
advantages, including flexibility for the total sample size. 
The NHIS includes the noninstitutionalized civilian population residing in the 
United States at the time of the interview (National Center for Health Statistics, 2015b, 
2016b, 2017b). Individuals excluded from the survey include long-term care facility 
patients, individuals on active duty with the Armed Forces, incarcerated persons, and 
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U.S. nationals living outside the U.S (National Center for Health Statistics, 2015b, 2016a, 
2017b). For the family core component, adult members of the household available at 
interview time are invited to participate. For each household with children, a sample 
adult 18 years of age and over and a sample child under the age of 17 is randomly chosen 
to participate in the survey (CDC, 2018). In addition, the NHIS sample design 
oversamples non-White individuals to make sure all races are represented in the study. 
Information about the sample child is acquired from an adult residing in the household 
who is knowledgeable about the child’s health (CDC, 2018). 
The NHIS is conducted using computer-assisted personal interviewing (National 
Center for Health Statistics, 2015b, 2016b, 2017b). The computer-assisted personal 
interviewing data collection method includes computer software that guides the 
interviewer through the questionnaire where the interviewer enters responses into the 
computer (CDC, 2018). Subsequent survey questions are based on answers to previous 
questions, and the responses data is automatically saved in the survey data file (CDC, 
2018). 
Participation in the survey is voluntary, and the confidentiality of responses is 
guaranteed under Section 308(d) of the Public Health Service Act (CDC, n.d.). 
Additionally, the National Center for Health Statistics must adhere to Section 308(d) of 
the Public Health Service Act (42 U.S.C. 242m) and the Confidential Information 
Protection and Statistical Efficiency Act (44 U.S.C. 3501 note) to protect the privacy of 
participants (National Center for Health Statistics, 2015b, 2016b, 2017b). The annual 
response rate of NHIS is roughly 70% of the qualified households in the sample (CDC, 
40 
 
2018). All individual identifying information collected by the NHIS is held confidential, 
and personal information is not disclosed or released to anyone without the consent of the 
respondent (CDC, 2018).  
Baseline Descriptive and Demographic Characteristics 
For the 2014-2015 flu season a total of 5,097 children received the flu vaccine, 
3,832 (75.2%) received the flu shot, and 1,265 (24.8%) the LAIV. The age range of 
children in the study was 0-17 years of age. Most participants for this flu season were 
covered by health insurance (96.8%) either private or public, and only 3.2% were 
uninsured. The largest ethnic group for this flu season was White individuals at 48.7% of 
the total population and “All Other Race Groups” was the least at 1.8% of the population. 
For the 2014-2015 flu season, family income ranged from $0-100,000+, with the largest 
population at the lowest and highest income groups. Table 5 includes socioeconomic 
status and demographic frequencies for the 2014-2015 flu season. 
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Table 5 
 
2014-2015 Socioeconomic and demographic Frequency Table 
Characteristics Frequency Percent Cumulative Percent 
Age    
   0-2 860 16.9 16.9 
   3-5 946 18.6 35.4 
   6-8 874 17.1 52.6 
   9-11 818 16.0 68.6 
   12-14 828 16.2 84.9 
   15-17 771 15.1 100.0 
Total 5097 100.0  
Insurance    
   Private 2793 54.8 54.8 
   Medicaid and Other 
Public 
2025 39.7 94.5 
   Other Coverage 114 2.2 96.8 
   Uninsured 165 3.2 100 
Total 5097 100  
Race    
   Hispanic 1480 29.0 29.0 
   White 2480 48.7 77.7 
   Black 644 12.6 90.3 
   Asian 402 7.9 98.2 
   All Other Race Groups 91 1.8 100 
Total 5097 100  
Family Income    
   $0-$34,999 1623 31.8 31.8 
   $35,000-$74,999 1389 27.3 59.1 
   $75,000-$99,999 592 11.6 70.7 
   $100,000 + 1493 29.3 100 
Total 5097 100  
Note. Data Source: NHIS, 2015. 
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For the 2015-2016 flu season a total of 5,676 children received the flu vaccine, 
3,766 (66.3%) received the flu shot, and 1,910 (33.7 %) LAIV. The age range of children 
in the study was 0-17 years of age. Most participants for this flu season had health 
coverage (97.1%) either private or public, and only 2.9% were uninsured. The largest 
ethnic group for the 2015-2016 flu season was White at 56.7% of the total population, 
and “All Other Race Groups” was the least at 2.4% of the population. Family income for 
2016 ranged from $0-100,000+, with the largest population at the second lowest and 
highest income groups. Table 6 includes socioeconomic and demographic frequencies for 
the 2015-2016 flu season. 
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Table 6 
 
2015-2016 Socioeconomic and Demographic Frequency Table 
Characteristics  Frequency Percent Cumulative Percent 
Age     
   0-2 876 15.4 15.4 
   3-5 1099 19.4 34.8 
   6-8 990 17.4 52.2 
   9-11 917 16.2 68.4 
   12-14 941 16.6 85.0 
   15-17 853 15.0 100.0 
Total 5676 100.0  
Insurance     
   Private  3363 59.2 59.2 
   Medicaid and Other Public  1961 34.5 93.8 
   Other Coverage  189 3.3 97.1 
   Uninsured  163 2.9 100 
Total  5676 100  
Race     
   Hispanic  1216 21.4 21.4 
   White  3217 56.7 78.1 
   Black  679 12.0 90.1 
   Asian 428 7.5 97.6 
   All Other Race Groups  136 2.4 100 
Total  5676 100  
Family Income     
   $0-$34,999 1460 25.7 25.7 
   $35,000-$74,999 1503 26.5 52.2 
   $75,000-$99,999 746 13.1 65.3 
   $100,000 + 1967 34.7 100 
Total  5676 100  
Note. Data Source: NHIS, 2016. 
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For the 2016-2017 flu season a total of 3,795 children received the flu vaccine, 
3,263 (86.0%) received the flu shot, and 532 (14%) the LAIV. The age range of children 
in the study was 0-17 years of age. Most participants for this flu season had health 
coverage (97.3%) either private or public, and only 2.7% were uninsured. The largest 
ethnic group for the 2016-2017 flu season was White individuals at 56.3% of the total 
population, and “All Other Race Groups” was the least at 2.1% of the population. Family 
income for 2017 ranged from $0-100,000+, with the largest population at the second 
lowest and highest income groups. Table 7 includes socioeconomic and demographic 
frequencies for the 2016-2017 flu season.  
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Table 7 
 
2016-2017 Socioeconomic and Demographic Frequency Table 
Characteristics  Frequency Percent Cumulative Percent 
Age     
   0-2 621 16.4 16.4 
   3-5 665 17.5 33.9 
   6-8 677 17.8 51.7 
   9-11 606 16.0 67.7 
   12-14 628 16.5 84.2 
   15-17 598 15.8 100.0 
Total 3795 100.0  
Insurance     
   Private  2262 59.6 59.6 
   Medicaid and Other Public  1277 33.6 93.3 
   Other Coverage  155 4.1  97.3 
   Uninsured  101 2.7 100 
Total  3795 100  
Race     
   Hispanic  852 22.5 22.5 
   White  2137 56.3 78.8 
   Black  437 11.5 90.3 
   Asian 290 7.6 97.9 
   All Other Race Groups  79 2.1 100 
Total  3795 100  
Family Income     
   $0-$34,999 946 24.9 24.9 
   $35,000-$74,999 969 25.5 50.5 
   $75,000-$99,999 426 11.2 61.7 
   $100,000 + 1454 38.3 100 
Total  3795 100  
Note. Data Source: NHIS, 2017. 
  
46 
 
For all three seasons (2015, 2016, and 2017) a total of 32,243 children ages 0-17 
were included in the data set. Of those children, 15,170 (48.6%) children ages 0-17 
received the flu vaccine, and 16,052 (51.4%) did not receive the flu vaccine. According 
to the NHIS survey data, 11,922 (81.5%) received the flu shot, and 2,700 (18.5 %) 
received the flu nasal spray combined over all three flu seasons.  
Statistical Assumptions 
Research Questions 1-3: Binomial Logistic Regression 
The assumptions of a binomial logistic regression provide information on the 
accuracy of the predictions, test how well the regression model fits the data, determine 
the variation in the dependent variable explained by the independent variables, and test 
hypotheses on the regression equation (Laerd Statistics, 2015). The assumptions for this 
study were: 
• Assumption #1: One dependent variable that is dichotomous (LAIV and IIV) 
• Assumption #2: One or more independent variables that are measured on 
either a continuous or nominal scale (age, race, health insurance status, family 
income).  
• Assumption #3: Independence of observations and the categories of the 
dichotomous dependent variable and all your nominal independent variables 
should be mutually exclusive and exhaustive. Independence of observations is 
largely a study design issue rather than something you can test for using SPSS 
Statistics. 
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• Assumption #4: A bare minimum of 15 cases per independent variable, 
although some recommend as high as 50 cases per independent variable. 
• Assumption #5: A linear relationship between the continuous independent 
variables and the logit transformation of the dependent variable. This research 
question does not include continuous variables, so a linear relationship is not 
necessary between variables. 
• Assumption #6: Data must not show multicollinearity, correlation coefficients 
and Tolerance/VIF values found no multicollinearity among variables.  
• Assumption #7: No significant outliers, high leverage points or highly 
influential points. No significant outliers were identified. 
Research Question 4: Chi-Square Test of Homogeneity Statistical Assumptions 
The chi-square test of homogeneity is used to determine if a difference exists 
between the binomial proportions of three or more independent groups on a dichotomous 
dependent variable. It will let you determine whether the proportions are statistically 
significantly different in the different groups. If there are statistically significant 
differences in proportions, a post hoc test to determine where the differences between 
these groups lie can be used (Laerd Statistics, 2017).  
• Assumption #1: One dependent variable that is measured at the dichotomous 
level (LAIV/ IIV). 
• Assumption #2: One independent variable that is polytomous, Flu vaccine 
years (2015, 2016, and 2017).  
48 
 
• Assumption #3: Independence of observations, which means that there is no 
relationship between the observations in each group of the independent 
variable. Participants for each year were different based on the sampling 
method identified by the NHIS.  
• Assumptions #4: Study type includes random sampling from three or more 
independent populations. Each year was a different subset of the population.  
• Assumptions #5: A sufficiently large sample size so that the approximation to 
the chi-squared distribution is valid. The sample size includes a total of 13,347 
children ages 0-17.  
Results 
Data Analysis Research Question 1 
Research Question 1: What was the relationship between age, race, family 
income, insurance status, and vaccine type (LAIV/ IIV) among U.S. children for flu 
season 2014-2015?   
H01: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015. 
Ha1: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2014-2015 
Analysis of the 2014-2015 flu season. A 2-step procedure was used to assess the 
relationship of age, race, health insurance status and family income on vaccine uptake 
(LAIV vs. IIV). The first step used a Pearson’s chi-squared cross-tabulation to assess 
how each independent variable by itself was distributed between vaccine type. This was 
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used to provide a preliminary look at any potential imbalances across vaccine type. The 
second step employed binomial logistic regression to assess the impact of the 
independent variables when evaluated together. 
An odds ratio is calculated for each independent variable from the logistic 
regression model. The odds ratio is a measure of association between an exposure and an 
outcome (Szumilas, 2010) and the odds that the LAIV vaccine will be given based on a 
particular characteristic (socioeconomic-demographic status), compared to the odds of 
the LAIV vaccine being administered in the absence of that characteristic 
(socioeconomic-demographic status; Szumilas, 2010). This provides the change in the 
odds for each increase in one unit of the independent variable (Szumilas, 2010). Odds 
ratios are used to compare the relative odds of the occurrence of the outcome of interest 
(LAIV), given exposure to the variable of interest (socioeconomic-demographic status).  
A 95 % confidence interval (CI) is used to estimate the precision of the odds ratio 
(Szumilas, 2010). A large CI indicates a low level of precision and a small CI indicates a 
higher precision of the odds ratio (Szumilas, 2010). Unlike the p-value, the 95 % CI does 
not report a measure’s statistical significance rather the 95 % CI is often used as a proxy 
for the presence of statistical significance if it does not include the null value of odds 
ratio = 1 (Szumilas, 2010). 
Tables 8-11 show how the socioeconomic and demographic variables are 
distributed among vaccine recipients their impact on vaccine type. Overall, many more 
patients received IIV compared to LAIV in the 2014-2015 flu season (75.2% vs. 24.8%). 
Table 8 shows that the distributions of ages differed by vaccine type. In the IIV group, 
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the percentage within each age category ranged from a low of 10.9 % (9-11year old) to a 
high of 15.0 % (ages 0-2 years old) with an average age of 6-8. Within the LAIV group 
the range of percentages within each age category range from a low of 7.4 % (0-2 years 
of age) to a high of 24.7 % (6-8 years old) with an average age of 6-8. 
Table 8 
 
2014-2015 Age and Vaccine Type Frequencies  
 
Age  
Vaccine type  
Total IIV LAIV 
0-2 767 (20.0%) 93 (7.4%) 860 (16.9%) 
3-5 672 (17.5%) 274 (21.7%) 946 (18.6%) 
6-8 561 (14.6%) 313 (24.7%) 874 (17.1%) 
9-11 557 (14.5%) 261(20.6%) 818 (16.0%) 
12-14 628 (16.4%) 200 (15.8%) 828 (16.2%) 
15-17 647 (16.9%) 124 (9.8%) 771 (15.1%) 
Total  3832 (75.2%) 1265 (24.8%) 5097 (100.0%) 
Note. Data Source: NHIS, 2015. 
  
Table 9 describes insurance coverage by vaccine type. Most participants had some 
type of insurance coverage (96.3% for IIV, 98.1% for LAIV). More participants receiving 
IIV had public insurance compared to those receiving LAIV (41.6% vs. 33.9%) while the 
opposite was true for those having private insurance (52.5% for IIV, 61.8% for LAIV).  
Table 9 
 
2014-2015 Health Coverage and Vaccine Type Frequencies 
 
Health Coverage  
Vaccine type  
Total IIV LAIV 
Private 2011(52.5%) 782 (61.8%)  2793 (54.8%) 
Medicaid and other public 1596 (41.6%) 429 (33.9%) 2025 (39.7%) 
Other Coverage 84 (2.2%) 30 (2.4%) 114 (2.2%) 
Uninsured 141 (3.7%) 24 (1.9%) 165 (3.2%) 
Total  3832 (75.2%) 1265 (24.8%) 5097 (100.0%) 
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Note. Data Source: NHIS, 2015. 
 
Table 10 describes the distribution of race which differed between vaccine type. 
Most vaccine recipients were Hispanic (31.2%IIV, 22.6% LAIV) or White (45.7% IIV, 
57.5% LAIV).  
Table 10 
 
2014-2015 Race and Vaccine Type Frequencies  
 
Race  
Vaccine type  
Total IIV LAIV 
Hispanic 1194 (31.2%) 286 (22.6%) 1480 (29.0%) 
White 1753 (45.7%) 727 (57.5%) 2480 (48.7%) 
Black 500 (13.0%) 144 (11.4%) 644 (12.6%) 
Asian 314 (8.2%) 88 (7.0%) 402 (7.9%) 
All other race groups 71 (1.9%) 20 (1.6%) 91 (1.8%) 
Total  3832 (75.2%) 1265 (24.8%) 5097 (100.0%) 
Note. Data Source: NHIS, 2015. 
 
Table 11 describes family income. More IIV recipients were in the lowest income 
group (33.7% vs. 26.2% for LAIV) while more recipients in the LAIV group were in the 
highest income group (36.5% vs. 26.9% for IIV). 
Table 11 
 
2014-2015 Family Income and Vaccine Type Frequencies  
 
Family Income  
Vaccine type  
Total IIV LAIV 
$0 - $34,999 1292 (33.7%) 331 (26.2%) 1623 (31.8%) 
$35,000 -$74,999 1080 (28.2%) 309 (24.4%) 1389 (27.3%) 
$75,000 -$99,999 429 (11.2%) 163 (12.9%) 592 (11.6%) 
$100,000 and over 1031 (26.9%) 462 (36.5%) 1493 (29.3%) 
Total  3832 (75.2%) 1265 (24.8%) 5097 (100.0%) 
Note. Data Source: NHIS, 2015. 
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Logistic regression was used to describe the data and explain any relationship 
between vaccine type and the independent variables (covariates). Logistic regression 
using vaccine type (probability modeled as LAIV) was applied to assess the relationship 
amongst age group, insurance type, race, family income.  
A model containing all 4 covariates was run. Before interpreting the model, the 
model containing covariates needs to be checked that at least 1 covariate is different from 
0 by testing that the global null hypothesis=0. A p-value<0.0001 was obtained allowing 
for rejection of this null hypothesis. This suggests that at least 1 covariate in the model is 
different from 0. In addition, a goodness-of-fit statistic, the Hosmer-Lemeshow test, is 
applied to the resulting model to check that the model is correctly specified, the data do 
not conflict with the assumptions made by the model.  The obtained p-value=0.344 
suggests that we cannot reject the hypothesis that the fitted model is correct.  
The reduced model was determined a better fit when health insurance status was 
determined not significant through initial analysis. Table 13 shows the results of the 
reduced logistic regression analysis used to address Research Question 1. The logistic 
regression model was statistically significant, χ2(15) = 315.831, p = .000. The Wald test 
of significance indicated that age (p = .000), race (p = .000), and family income (p = 
.000) were all statistically significant in relation to LAIV uptake.   
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Table 12 
 
Logistic Regression Reduced Model Flu Season 2014-2015 
       95% CI for 
Exp(B) 
 B S.E. Wald df Sig. Exp(B) Lower Upper 
Age   198.965 5 .000    
3-5 1.223 .132 85.877 1 .000 3.397 2.623 4.400 
6-8 1.542 .131 137.614 1 .000 4.674 3.612 6.047 
9-11 1.356 .134 102.453 1 .000 3.882 2.985 5.048 
12-14 .967 .138 49.450 1 .000 2.630 2.009 3.444 
15-17 .435 .148 8.641 1 .003 1.545 1.156 2.066 
Race   30.495 4 .000    
White .421 .087 23.457 1 .000 1.523 1.285 1.806 
Black .181 .118 2.368 1 .124 1.199 .952 1.509 
Asian -.027 .145 .036 1 .851 .973 .732 1.293 
Other race groups .196 .268 .535 1 .465 1.217 .719 2.058 
Family income   26.992 3 .000    
35,000-74,999 .041 .092 .197 1 .657 1.042 .869 1.249 
75,000-99,999 .310 .117 7.001 1 .008 1.363 1.084 1.715 
100,000+ .422 .093 20.468 1 .000 1.524 1.270 1.830 
Constant -2.535 .132 369.371 1 .000 .079   
Note. Data Source: NHIS, 2015. Variable(s) entered on step 1: Age, Health coverage, 
Race, Family Income. Comparison groups are age (0-2), Race (Hispanic), Family income 
($0-34,999), and health coverage (private).  
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In the full model three of the four covariates are significant (p < 0.05) with only 
insurance coverage (p = 0.115) not statistically significant. As a result, a reduced model 
eliminating insurance coverage from the model was run. The Hosmer-Lemeshow statistic 
from the reduced model was p = 0.393 suggesting a slightly better fit to the data. As a 
result, inferences are based on this reduced model. The odds ratios are shown in Table 13.  
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Table 13 
 
2014-2015 Socioeconomic, Demographic, and Vaccine Type Odds Ratios 
Odds Ratio Estimates and Wald Confidence Intervals 
  
Independent Variables 
 
Odds Ratio 
 
95% Confidence Limits 
Race  White vs. Hispanic 1.523 1.285 1.806  
Black vs. Hispanic 1.199 0.952 1.509 
Asian vs. Hispanic 0.973 0.732 1.293 
All other races vs. Hispanic  1.217 0.719 2.058 
White vs. Black  1.271 1.023 1.579 
White vs. Asian 1.565 1.209 2.027 
White vs. All other races  1.252 0.745 2.105 
Black vs. Asian 1.232 0.900 1.686 
Black vs. All other races 0.985 0.572 1.696 
Asian vs. All other races 0.800 0.454 1.410 
Age  3-5 vs. 0-2  3.396 2.622 4.398 
6-8 vs. 0-2 4.673 3.611 6.045 
9-11 vs. 0-2 3.881 2.985 5.047 
12-14 vs. 0-2 2.629 2.008 3.443 
15-17 vs. 0-2 1.545 1.156 2.065 
3-5 vs. 6-8 0.727 0.596 0.887 
3-5 vs. 9-11 0.875 0.712 1.075 
3-5 vs. 12-14 1.292 1.042 1.601 
3-5 vs. 15-17 2.198 1.729 2.795 
6-8 vs 9-11 1.204 0.982 1.477 
6-8 vs 12-14 1.777 1.436 2.199 
6-8 vs 15-17 3.025 2.382 3.841 
9-11 vs 12-14 1.476 1.186 1.837 
9-11 vs 15-17 2.512 1.968 3.207 
12-14 vs 15-17  1.702 1.324 2.189 
Family  
Income  
$ 35 -74,999 vs. $ 0-34,999 1.042 0.868 1.249 
$ 75 -99,999 vs. $ 0-34,999 1.363 1.084 1.715 
$ 100,000 + vs. $ 0-34,999 1.524 1.270 1.830 
$ 35 -74,999 vs. $ 75 -99,999 0.764 0.609 0.960 
$ 35 -74,999 vs. $ 100,000 + 0.683 0.572 0.816 
$ 75 -99,999 vs. $ 100,000 + 0.894 0.719 1.112 
Note. Data Source: NHIS, 2015. 
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The highest odds ratios were for children among the 6-8 age group who were 
4.673 times more likely to receive the LAIV vaccine than children ages 0-2 and 3.025 
times more likely to receive LAIV than children ages 15-17. Children ages 0-2, in which 
LAIV is not recommended for, were less likely overall to receive LAIV than all other age 
groups in the study. Children ages 9-11 were also more likely to receive the LAIV 
vaccine than their peers as they fit into the ACIP age recommendation group.  
White children were 1. 565 times more likely to receive the LAIV vaccine than 
Asian children. In fact, White children were more likely to receive the LAIV vaccine than 
Black (1.271) and Hispanic (1.523) children as well.  
Children with a family income of $100,000 or more were 1.524 times more likely 
to receive the LAIV vaccine than those with a family income of $0- 34,999 annually. 
Children with a family income of $75 -99,999 were 1.363 times more likely to receive 
the LAIV vaccine than those with a family income of $0- 34,999 annually.  
 For Research Question 1, we reject the null hypothesis in favor of the alternative 
hypothesis for race, age, and family income and we fail to reject the null for health 
insurance coverage. There is a relationship between age, race, family income and vaccine 
type (LAIV/ IIV) among U.S. children for flu season 2014-2015. Those who received 
LAIV were most likely to be White elementary school age children with a family income 
of 75,000+ for the 2014-2015 flu season. Health insurance coverage was very high for 
this population (96.3% for IIV, 98.1% for LAIV) indicating that the sample of uninsured 
individuals may have been too low to address a relationship among variables. In addition, 
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most of the LAIV cases were clustered around the ACIP recommended age of 2-8 years 
of age considered the preferred flu vaccine type for the 2014-2015 flu season.  
Data Analysis Research Question 2  
Research Question 2: What was the relationship between age, race, family 
income, health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for 
flu season 2015-2016?   
H02: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016. 
Ha2: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/IIV) among U.S. children for flu season 2015-2016. 
Analysis of the 2015-2016 flu season. The same analysis approach as used in 
Research Question 1 was also used for Research Question 2. Chi-square was used to 
assess each independent variable by itself, and logistic regression was used to evaluate 
these variables in a model. Tables 14- 17 show how the socioeconomic and demographic 
variables are distributed among vaccine recipients their impact on vaccine type. As in 
2014-2015, more patients received IIV compared to LAIV in the 2015-2016 flu season 
(79.8% vs. 20.2%). Table 14 shows that the distributions of ages differed by vaccine 
type. In the IIV group, the percentage within each age category ranged from a low of 13.7 
% (9-11year old) to a high of 18.9 % (ages 0-2 years old) with an average age of 6-8. 
Within the LAIV group the range of percentages within each age category range from a 
low of 8.6 % (0-2 years of age) to a high of 23.4 % (6-8 years old) with an average age of 
6-8. 
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Table 14 
 
2015-2016 Age and Vaccine Type Frequencies  
 
Age  
Vaccine type  
Total IIV LAIV 
0-2 712 (18.9%) 82 (8.6%) 794 (16.8%) 
3-5 703 (18.7%) 198 (20.7%) 901 (19.1%) 
6-8 544 (14.4%) 223 (23.4%) 767 (16.2%) 
9-11 517 (13.7%) 200 (20.9%) 717 (15.2%) 
12-14 639 (17.0%) 151 (15.8%) 790 (16.7%) 
15-17 651 (17.3%) 101 (10.6%) 752 (15.9%) 
Total  3766 (79.8%) 955 (20.2%) 4721 (100.0%) 
Note. Data Source: NHIS, 2016. 
  
Table 15 describes insurance coverage by vaccine type. Most participants had 
some type of insurance coverage (97.8% for IIV, 99.4% for LAIV). More participants 
receiving IIV had public insurance compared to those receiving LAIV (35.5% vs. 
32.7.0%) and private insurance (58.5% for IIV, 60.7% for LAIV).  
Table 15 
 
2015-2016 Health Coverage and Vaccine Type Frequencies  
 
Health Coverage  
Vaccine type  
Total IIV LAIV 
Private 2203 (58.5%) 580 (60.7%) 2783 (58.9%) 
Public 1337 (35.5%) 312 (32.7%) 1649 (34.9%) 
Other coverage 121 (3.2%) 34 (3.6%) 155 (3.3%) 
Uninsured 105 (2.8%) 29 (3.0%) 134 (2.8%) 
Total  3766 (79.8%) 955 (20.2%) 4721 (100.0%) 
Note. Data Source: NHIS, 2016. 
 
Table 16 describes the distribution of race which differed between vaccine type. 
Most vaccine recipients were either White (54.8% IIV, 60.4% LAIV) or Hispanic 
(22.2%IIV, 19.9% LAIV). 
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Table 16 
 
2015-2016 Race and Vaccine Type Frequencies  
 
Race  
Vaccine type  
Total IIV LAIV 
Hispanic 836 (22.2%) 190 (19.9%) 1026 (21.7%) 
White 2063 (54.8%) 577 (60.4%) 2640 (55.9%) 
Black 459 (12.2%) 110 (11.5%) 569 (12.1%) 
Asian 302 (8.0%) 63 (6.6%) 365 (7.7%) 
All other race groups 106 (2.8%) 15 (1.6%) 121 (2.6%) 
Total 3766 (79.8%) 955 (20.2%) 4721 (100.0%) 
Note. Data Source: NHIS, 2016. 
 
Table 17 describes family income. Family income was similar for both IIV and 
LAIV recipients. Twenty-six % of children who received the flu vaccine were in the 
lowest income group (IIV 26.4% and LAIV 24.3%) and 34.4 %were in the highest 
income group (LAIV 35.9% and 34% for IIV). 
Table 17 
 
2015-2016 Family Income and Vaccine Type Frequencies  
 
Family Income  
Vaccine type  
Total IIV LAIV 
$0 -$34,999 996 (26.4%) 232 (24.3%) 1228 (26.0%) 
$35,000 - $74,999 991 (26.3%) 256 (26.8%) 1247 (26.4%) 
$75,000 - $99,999 498 (13.2%) 124 (13.0%) 622 (13.2%) 
$100,000 + 1281 (34.0%) 343 (35.9%) 1624 (34.4%) 
Total  3766 (79.8%) 955 (20.2%) 4721 (100.0%) 
Note. Data Source: NHIS, 2016. 
 
Logistic regression was used to describe the data and explain any relationship 
between vaccine type and the independent variables (covariates). Logistic regression 
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using vaccine type (probability modeled as LAIV) was applied to assess the relationship 
amongst age group, insurance type, race, family income.  
The reduced model was determined a better fit when health insurance status and 
family income were determined not significant through initial analysis. The logistic 
regression model was statistically significant, χ2(15) = 262.482, p = .000. The Wald test 
of significance indicated that age (p = .000) and race (p= .000) were all statistically 
significant in relation to LAIV uptake. Table 18 shows the results of the logistic 
regression analysis used to address Research Question 2.  
Table 18 
 
Logistic Regression Reduced Model Flu Season 2015-2016 
       95% CI for 
Exp(B) 
 B S.E. Wald df Sig. Exp(B) Lower Upper 
Age   220.61 5 .000    
3-5 .894 .107 69.557 1 .000 2.445 1.982 3.017 
6-8 1.273 .108 139.332 1 .000 3.571 2.891 4.412 
9-11 1.221 .110 124.323 1 .000 3.391 2.736 4.203 
12-14 .729 .112 42.687 1 .000 2.073 1.666 2.579 
15-17 .295 .118 6.197 1 .013 1.343 1.065 1.694 
Race   23.707 4 .000    
White .228 .073 9.595 1 .002 1.256 1.087 1.450 
Black .058 .105 .303 1 .582 1.059 .863 1.301 
Asian -.089 .125 .499 1 .480 .915 .716 1.170 
Other race groups -.462 .219 4.442 1 .035 .630 .410 .968 
Constant -.911 .053 297.960 1 .000 .402   
Note. Data Source: NHIS, 2016. 
 
Two of the four covariates are significant (p < 0.05). Insurance coverage (p = 
0.652) and family income (p = 0.920) were not statistically significant. Based on this a 
reduced model eliminating insurance coverage from the model was run. The Hosmer-
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Lemeshow statistic from the reduced model was p = 0.4390 suggesting a slightly better 
fit to the data. As a result, inferences are based on this reduced model. 
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Table 19 
 
2015-2016 Demographic characteristics and Vaccine Type Odds Ratios  
Odds Ratio Estimates and Wald Confidence Intervals 
  
Independent Variables 
 
Odds Ratio 
 
95% Confidence Limits 
Race  White vs. Hispanic 1.261 1.047 1.517 
Black vs. Hispanic 1.059 0.813 1.379 
Asian vs. Hispanic 0.920 0.669 1.265 
All other races vs. Hispanic  0.627 0.355 1.107 
White vs. Black  1.191 0.945 1.500 
White vs. Asian 1.370 1.024 1.833 
White vs. All other races  2.011 1.156 3.500 
Black vs. Asian 1.115 0.813 1.627 
Black vs. All other races 1.689 0.940 3.032 
Asian vs. All other races 1.468 0.796 2.706 
Age  3-5 vs. 0-2  2.453 1.857 3.239 
6-8 vs. 0-2 3.590 2.755 4.737 
9-11 vs. 0-2 3.398 2.565 4.503 
12-14 vs. 0-2 2.084 1.559 2.785 
15-17 vs. 0-2 1.351 0.991 1.843 
3-5 vs. 6-8 0.683 0.547 0.853 
3-5 vs. 9-11 0.722 0.575 0.906 
3-5 vs. 12-14 1.177 0.928 1.493 
3-5 vs. 15-17 1.815 1.396 2.361 
6-8 vs 9-11 1.057 0.843 1.325 
6-8 vs 12-14 1.723 1.360 2.183 
6-8 vs 15-17 2.657 2.046 3.452 
9-11 vs 12-14 1.631 1.281 2.076 
9-11 vs 15-17 2.515 1.928 3.282 
12-14 vs 15-17  1.542 1.171 2.031 
Note. Data Source: NHIS, 2016. 
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The highest odds ratios were for children among the 6-8 age group who were 
3.590 times more likely to receive the LAIV vaccine than children ages 0-2 and 65% 
more likely to receive LAIV than children ages 15-17. Children ages 0-2 were less likely 
overall to receive LAIV than all other age groups in the study. Children ages 9-11 and 
12-14 were also more likely to receive the LAIV vaccine than their peers. White children 
were 1.370 times more likely to receive the LAIV vaccine than Asian children. In fact, 
White children were more likely to receive the LAIV vaccine than Black (1.191), 
Hispanic (1.261), and all other race (2.011) children as well. For Research Question 2, 
the reduced model including race and age provided the best fit. showing there these 
variables and vaccine type (LAIV/ IIV) among U.S. children for flu season 2015-2016. 
Those who received LAIV during the 2015-2016 flu season were also most likely to be 
White elementary school age children.  
Data Analysis Research Question 3  
Research Question 3: What was the relationship between age, race, family 
income, health insurance status, and vaccine type (LAIV/ IIV) among U.S. children for 
flu season 2016-2017?   
H03: There is no relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017. 
Ha3: There is a relationship between age, race, family income, health insurance 
status, and vaccine type (LAIV/ IIV) among U.S. children for flu season 2016-2017. 
Analysis of the 2016-2017 flu season. The same statistical approach was used as 
was used for Research Question 1 and Research Question 2. Tables 20- 23 show how the 
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socioeconomic-demographic variables are distributed among vaccine recipients their 
impact on vaccine type. Overall, many more patients received IIV compared to LAIV in 
the 2015-2016 flu season (92.5% vs. 7.5%). Table 20 shows that the distributions of ages 
differed by vaccine type. In the IIV group, the percentage within each age category 
ranged from a low of 14.8 % (9-11year old) to a high of 18.1 % (ages 3-5years old) with 
an average age of 6-8. Within the LAIV group the range of percentages within each age 
category range from a low of 11.3 % (15-17 years of age) to a high of 24.1% (6-8 years 
old) with an average age of 6-8. 
Table 20 
 
2016-2017 Age and Vaccine Type Frequencies  
 
Age 
Vaccine type  
Total IIV LAIV 
0-2 555 (17.0%) 33 (12.4%) 588 (16.7%) 
3-5 591(18.1%) 37 (13.9%) 628 (17.8%) 
6-8 549 (16.8%) 64 (24.1%) 613 (17.4%) 
9-11 484 (14.8%) 61(22.9%) 545 (15.4%) 
12-14 546 (16.7%) 41(15.4%) 587 (16.6%) 
15-17 538 (16.5%) 30 (11.3%) 568 (16.1%) 
Total  3263 (92.5%) 266 (7.5%) 3529 (100.0%) 
Note. Data Source: NHIS, 2017. 
 
Table 21 describes insurance coverage by vaccine type. Most participants had 
some type of insurance coverage (97.3% for IIV, 97.7% for LAIV). More participants 
receiving LAIV had public insurance compared to those receiving the Flu shot (35.3% vs. 
33.4%) while the opposite was true for those having private insurance (60.0% for IIV, 
57.1% for LAIV).  
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Table 21 
 
2016-2017 Health Coverage and Vaccine Type Frequencies  
 
Health Coverage  
 Vaccine type  
Total IIV LAIV 
Private 1958 (60.0%) 152 (57.1%) 2110 (59.8%) 
 Public 1089 (33.4%) 94 (35.3%) 1183 (33.5%) 
Other coverage 127 (3.9%) 14 (5.3%) 141(4.0%) 
Uninsured 89 (2.7%) 6 (2.3%) 95 (2.7%) 
Total  3263 (92.5%) 266 (7.5%) 3529 (100.0%) 
Note. Data Source: NHIS, 2017. 
 
Table 22 describes the distribution of race which differed between vaccine type. 
Most vaccine recipients were Hispanic (22.5%IIV, 22.2% LAIV) or White (56.7% IIV, 
53.8% LAIV).  
Table 22 
 
2016-2017 Race and Vaccine Type Frequencies  
 
Race  
 Vaccine type  
Total IIV LAIV 
Hispanic 734 (22.5%) 59 (22.2%) 793 (22.5%) 
White 1851(56.7%) 143 (53.8%) 1994 (56.5%) 
Black 357 (10.9%) 40 (15.0%) 397 (11.2%) 
Asian 258 (7.9%) 16 (6.0%) 274 (7.8%) 
All other race groups 63 (1.9%) 8 (3.0%) 71(2.0%) 
Total  3263 (92.5%) 266 (7.5%) 3529 (100%) 
Note. Data Source: NHIS, 2017. 
 
Table 23 describes family income. More IIV recipients were in the highest 
income group (38.4% vs. 37.6% for LAIV) while more recipients in the LAIV group 
were in the lowest income group (24.6% vs. 27.1% for IIV). 
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Table 23 
 
2016-2017 Family Income and Vaccine Type Frequencies  
 
Family Income  
 Vaccine type  
Total IIV LAIV 
$0 - $34,999 802 (24.6%) 72 (27.1%) 874 (24.8%) 
$35,000 - $74,999 831 (25.5%) 69 (25.9%) 900 (25.5%) 
$75,000 - $99,999 376 (11.5%) 25 (9.4%) 401(11.4%) 
$100,000 and over 1254 (38.4%) 100 (37.6%) 1354 (38.4%) 
Total  3263 (92.5%) 266 (7.5%) 3529 (100%) 
Note. Data Source: NHIS, 2017. 
 
Logistic regression was used to describe the data and explain any relationship 
between vaccine type and the independent variables (covariates). Logistic regression 
using vaccine type (probability modeled as LAIV) was applied to assess the relationship 
amongst age group, insurance type, race, family income.  
Before interpreting the model, the model containing covariates needs to be 
checked that at least 1 covariate is different from 0 by testing that the global null 
hypothesis=0. A p-value<0.0001 was obtained allowing for rejection of this null 
hypothesis. This suggests that at least 1 covariate in the model is different from 0. In 
addition, a goodness-of-fit statistic, the Hosmer-Lemeshow test, is applied to the resulting 
model to check that the model is correctly specified, the data do not conflict with the 
assumptions made by the model.  The obtained p-value=0.818 suggests that we cannot 
reject the hypothesis that the fitted model is correct.  
The reduced model was determined a better fit when health insurance status was 
determined not significant through initial analysis. Table 25 shows the results of the 
logistic regression analysis used to address Research Question 3.  The logistic regression 
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model was statistically significant, χ2(15) = 34.831, p = .003. The Wald test of 
significance indicated that age (p = .000) and race (p = .027) were statistically significant 
in relation to LAIV uptake.  
Table 24 
 
Logistic Regression Reduced Model Flu Season 2016-2017 
       95% CI for 
Exp(B) 
 B S.E. Wald df Sig. Exp(B) Lower Upper 
Age   48.972 5 .000    
3-5 .041 .180 .053 1 .819 1.042 .733 1.482 
6-8 .670 .163 16.798 1 .000 1.954 1.418 2.691 
9-11 .734 .166 19.685 1 .000 2.084 1.507 2.883 
12-14 .220 .176 1.550 1 .213 1.246 .881 1.760 
15-17 -.069 .189 .134 1 .714 .933 .645 1.351 
Race   10.942 4 .027    
White -.039 .119 .105 1 .745 .962 .762 1.214 
Black .299 .160 3.499 1 .061 1.349 .986 1.846 
Asian -.280 .213 1.722 1 .189 .756 .497 1.148 
Other race groups .470 .300 2.456  1 .117 1.599 .889 2.878 
Constant -1.774 .077 529.903 1 .000 1.70   
Note. Data Source: NHIS, 2017. 
 
Two of the four covariates are significant (p<0.05). Insurance coverage (p = 
0.778) and Family Income (p = 0.761) were not statistically significant. Based on this a 
reduced model eliminating insurance coverage from the model was run. The Hosmer-
Lemeshow statistic from the reduced model was p = 0.170 suggesting a better fit to the 
data. As a result, inferences are based on this reduced model. Table 25 shows the odds 
ratios and CIs for the 2016-2017 flu season.  
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Table 25 
 
2016-2017 Demographic Characteristics and Vaccine Type Odds Ratios 
Odds Ratio Estimates and Wald Confidence Intervals 
 
Independent Variables 
 
Odds Ratio 
 
95% Confidence Limits 
White vs. Hispanic 1.777 1.516 2.082 
Black vs. Hispanic 1.216 0.966 1.531 
Asian vs. Hispanic 1.155 0.878 1.520 
all other races vs. Hispanic  1.227 0.727 2.072 
White vs. Black  1.461 1.185 1.800 
White vs. Asian 1.538 1.190 1.989 
White vs. all other races  1.448 0.865 2.423 
Black vs. Asian 1.053 0.775 1.431 
Black vs. all other races 0.991 0.577 1.703 
Asian vs. all other races 0.941 0.537 1.650 
3-5 vs. 0-2  3.386 2.616 4.384 
6-8 vs. 0-2 4.667 3.609 6.035 
9-11 vs. 0-2 3.920 3.017 5.094 
12-14 vs. 0-2 2.676 2.045 3.502 
15-17 vs. 0-2 1.570 1.175 2.097 
3-5 vs. 6-8 0.726 0.595 0.885 
3-5 vs. 9-11 0.864 0.704 1.060 
3-5 vs. 12-14 1.265 1.022 1.567 
3-5 vs. 15-17 2.157 1.698 2.740 
6-8 vs 9-11 1.191 0.971 1.459 
6-8 vs 12-14 1.744 1.410 2.157 
6-8 vs 15-17 2.973 2.343 3.772 
9-11 vs 12-14 1.465 1.178 1.822 
9-11 vs 15-17 2.497 1.958 3.185 
12-14 vs 15-17  1.705 1.326 2.191 
Note. Data Source: NHIS, 2017. 
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The highest odds ratios were for children among the 6-8 age group were 4.667 
times more likely to receive the LAIV vaccine than children ages 0-2 and 3.920 times 
more likely to receive LAIV than children ages 9-11. Children ages 3-5 were less likely 
overall to receive LAIV than children 6-8 years of age. Children ages 0-2 were also more 
likely to receive the LAIV vaccine than their peers. White children were 1.777 times 
more likely to receive the LAIV vaccine than Hispanic children. In fact, White children 
were more likely to receive the LAIV vaccine than Black (1.461) and Asian (1.538) 
children. For Research Question 3, we reject the null hypothesis in favor of the 
alternative hypothesis for race and age; we fail to reject the null for health insurance 
coverage and family income. There is a relationship between age, race, and vaccine type 
(LAIV/ IIV) among U.S. children for flu season 2015-2016. Those who received LAIV 
during the 2016-2017 flu season were also most likely to be White elementary school age 
children.  
Data Analysis Research Question 4  
Research Question 4: What was the relationship between influenza vaccine type 
(LAIV/IIV) of U.S. children and ACIP recommendations indicated by flu seasons 2014-
2015, 2015-2016, and 2016-2017? 
H04: There is no relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015 (LAIV 
preferred), 2015-2016 (LAIV & IIV) and 2016-2017 (IIV preferred).  
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Ha4: There is a relationship between influenza vaccine type (LAIV/IIV) of U.S. 
children and ACIP recommendations indicated by flu seasons 2014-2015, 2015-2016, 
and 2016-2017. 
Analysis of three consecutive flu seasons. Due to lack of efficacy, ACIP did not 
recommend LAIV for the 2016-2017 flu season. A chi-square test of homogeneity was 
used to evaluate the relationship between ACIP recommendations by flu season and 
vaccine uptake (LAIV or IIV) to evaluate the impact of this change in recommendation. 
Table 26 shows the results by vaccine type. These results showed that IIV was the 
preferred vaccine for each year regardless of the ACIP recommendation. There was a 
statistically significant difference between all three independent binomial proportions 
χ2(2) = 423.238, p = 0.000 indicating that the proportion of patients receiving LAIV and 
IIV are significantly different. Approximately 75 % of patients received IIV, in 2014-
2015, and 2015-2016 and this increased to 92.5 % of patients receiving the vaccine in 
2016-2017. This reduction of LAIV use in the 2016-2017 flu season is consistent with 
ACIP recommendations. 
Table 26 
 
Flu Seasons and Vaccine Type Cross-Tabulation Post Hoc Test 
Vaccine 
Type  
Year  
Total 2014-2015 2015-2016 2016-2017 
IIV 3832a (75.2) 3766b (79.2) 3263c (92.5) 10861 (81.4) 
LAIV  1265a (24.8) 955b (20.2) 266c (7.5) 2486 (18.6) 
Total  5097  4721 3529 13347 
Note. Data Source: NHIS, 2015, 2016, 2017. 
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The next step was to evaluate if, in addition to ACIP recommendations changing, 
did any of the socioeconomic-demographic status variables also impacted or were they 
impacted by the change in recommendation. This was achieved by looking at the 
incidence of LAIV vaccination across the three flu seasons. Table 27 shows the age 
distribution of for all three Flu seasons for LAIV recipients only. Overall the number of 
children receiving LAIV in 2016-2017 was smaller than in earlier seasons indicating an 
impact of the ACIP recommendations. LAIV coverage was consistent across all age 
groups except the youngest (0-2) for all three years. Children ages 0-2 had a slight 
increase in LAIV uptake (12.4 %) for the 2016-2017 flu season even though LAIV is not 
recommended for their age group or the flu season. However, this must be interpreted 
based on the smaller number of children receiving LAIV in the 2016-2017 season. 
Table 27 
 
Age Distribution of LAIV Recipients for All Flu Seasons 
 
Age 
Year  
Total 2014-2015 2015-2016 2016-2017 
0-2 93 (7.4%) 82 (8.6%) 33 (12.4%) 208 (8.4%) 
3-5 274 (21.7%) 198 (20.7%) 37 (13.9%) 509 (20.5%) 
6-8 313 (24.7%) 223(23.4%) 64 (24.1%) 600 (24.1%) 
9-11 261 (20.6%) 200 (20.9%) 61(22.9%) 522 (21.0%) 
12-14 200 (15.8%) 151(15.8%) 41(15.4%) 392(15.8%) 
15-17 124 (9.8%) 101(10.6%) 30 (11.3%) 255(10.3%) 
Total  1265 955 266 2486 
Note. Data Source: NHIS, 2015, 2016, 2017. 
 
To further evaluate how socioeconomic status and demographic characteristics  
may influence the differences in LAIV vaccine uptake by year a chi-square test of 
homogeneity was conducted between flu season (2014-2015, 2015-2016, and 2016-2017) 
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by socioeconomic-demographic status (race, family income, and health insurance status) 
for LAIV recipients to determine if variations in socioeconomic-demographic status 
could account for the differences in LAIV uptake between Flu seasons 2014-2015, 2015-
2016 and 2016-2017. Table 28 shows the health insurance distribution of for all three Flu 
seasons for LAIV recipients only. Health insurance coverage among LAIV recipients 
remained consistent across all three flu seasons. No relationship between year and health 
coverage was observed (p = 0.087).  
Table 28 
 
Health Coverage of LAIV Recipients for All Flu Seasons  
 
Health Coverage 
Year  
Total 2014-2015 2015-2016 2016-2017 
Private 782 (61.8%) 580 (60.7%) 152 (57.1%) 1514 (60.9%) 
Medicaid/ Public 429 (33.9%) 312 (32.7%) 94 (35.3%) 835 (33.6%) 
Other Coverage 30 (2.4%) 34 (3.6%) 14 (5.3%) 78 (3.1%) 
Uninsured 24 (1.9%) 29 (3.0%) 6 (2.3%) 59 (2.4%) 
Total  1265 955 266 2486 
Note. Data Source: NHIS, 2015, 2016, 2017. 
 
Table 29 shows the race distribution of for all three Flu seasons for LAIV 
recipients only. Race was consistent across all three flu seasons. No relationship between 
year and race was observed (p = 0.303).  
Table 29 
 
Race Distribution of LAIV Recipients for All Flu Seasons 
 
Race 
Year  
Total 2014-2015 2015-2016 2016-2017 
Hispanic 286 (22.6%) 190 (19.9%) 59 (22.2%) 535 (21.5%) 
White 727 (57.5%) 577 (60.4%) 143 (53.8%) 1447 (58.3%) 
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Black 144 (11.4%) 110 (11.5%) 40 (15.0%) 294 (11.8%) 
Asian 88 (7.0%) 63 (6.6%) 16 (6.0%) 167 (6.7%) 
All other race 
groups 
20 (1.6%) 15 (1.6%) 8 (3.0%) 43 (1.7%) 
Total  1265 955 266 2486 
Note. Data Source: NHIS, 2015, 2016, 2017. 
 
Table 30 shows the family income distribution of for all three Flu seasons for 
LAIV recipients only. Family income was also consistent across all three flu seasons, 
with a minimal decline in the percent of LAIV recipients in the $75,000 to $99,999 
family income group from the 2014-2015 flu season (12.9%) to the 2016-2017 flu season 
(9.4%). No relationship between year and Family income was observed (p = 0.572). 
Table 30 
 
Family Income of LAIV Recipients for All Flu Seasons 
 
Family Income 
Year  
Total 2014-2015 2015-2016 2016-2017 
$0 - $34,999 331 (26.2%) 232 (24.3%) 72 (27.1%) 635 (25.5%) 
$35,000 -$74,999 309 (24.4%) 256 (26.8%) 69 (25.9%) 634 (25.5%) 
$75,000 -$99,999 163 (12.9%) 124 (13.0%) 25 (9.4%) 312 (12.6%) 
$100,000 and over 462 (36.5%) 343 (35.9%) 100 37.6%) 905 (36.4%) 
Total 1265 955 266 2486 
Note. Data Source: NHIS, 2015, 2016, 2017. 
 
All three flu seasons resulted in significantly different flu vaccine uptake by type 
consistent with ACIP recommendations. Socioeconomic status and demographic 
characteristics were not considered influential in LAIV uptake for race, health insurance 
status, or family income when comparing all three flu seasons. ACIP recommendations 
by age and year appeared to have the greatest impact on flu vaccine choice for this 
sample population.  
74 
 
Summary  
The purpose of this study is to examine the relationship between seasonal 
influenza vaccination ACIP recommendations, socioeconomic status, demographic 
characteristics, and vaccine uptake among children over three consecutive flu seasons. 
The dependent variable is influenza vaccine type (LAIV and IIV) among U.S. children. 
The independent variables are ACIP influenza vaccine recommendation by flu season 
including flu seasons 2014-2015, 2015-2016, and 2016-2017 and socioeconomic-
demographic status indicated by age, race, family income, and health insurance status. 
For research questions 1-3 forward, binomial logistic regression was performed to 
ascertain the effects of age, race, health insurance status, and family income on vaccine 
uptake by type LAIV or IIV. For research question 4 a chi-square test of homogeneity 
was used to evaluate the relationship between ACIP recommendations by flu season and 
vaccine uptake (LAIV or IIV) for all three flu seasons. These results showed that IIV was 
the preferred vaccine for each year regardless of the ACIP recommendation. To further 
evaluate how socioeconomic status and demographic characteristics may influence the 
differences in LAIV vaccine uptake by year a chi-square test of homogeneity was 
conducted between flu season (2014-2015, 2015-2016, and 2016-2017) by 
socioeconomic-demographic status (race, family income, and health insurance status) for 
LAIV recipients. 
For the 2014-2015 flu season, a relationship between age, race, family income, 
and vaccine type (LAIV/ IIV) was established among U.S. children included in this 
study. Those who received LAIV were most likely to be White elementary school age 
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children with a family income of 75,000+ for the 2014-2015 flu season. The 2015-2016 
and 2016-2017 flu seasons showed a relationship between demographic characteristics 
(age and race) and vaccine type (LAIV/ IIV) was established among U.S. children 
included in this study. Those who received LAIV during the 2015-2016 and 2016-2017 
flu season were also most likely to be White elementary school age children. All three flu 
seasons resulted is significantly different flu vaccine uptake by type consistent with ACIP 
recommendations. Socioeconomic status and demographic characteristics were not 
considered influential in LAIV uptake for race, health insurance status, or family income. 
ACIP recommendations by age and year appeared to have the greatest impact on flu 
vaccine choice for this sample population.  
Section 4 will present a summary of key findings, analyzes, interpretation, 
limitations to generalizability, validity, reliability, recommendations for further research, 
and implications for positive social change. 
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Section 4: Application to Professional Practice and Implications for Social Change  
Introduction 
I examined the relationship between seasonal influenza vaccination ACIP 
recommendations, socioeconomic status, demographic characteristics, and vaccine uptake 
among children over three consecutive flu seasons. LAIV was the recommended choice 
for children 2-8 during the 2014-2015 flu season, both LAIV and IIV were equally 
recommended for the 2015-2016 flu season, and the LAIV recommendation was 
discontinued for the 2016-2017 season due to studies showing limited efficacy against 
A/H1N1 (Flannery & Chung, 2016). In addition, multiple socioeconomic factors and 
demographic characteristics have the potential to influence vaccine choice. The 
dependent variable was influenza vaccine type (LAIV and IIV) among U.S. children. The 
independent variables were ACIP influenza vaccine recommendation by flu season 
(2014-2015, 2015-2016, and 2016-2017), and socioeconomic-demographic status 
indicated by age, race, family income, and health insurance status. Secondary 
surveillance data were taken from the CDC to evaluate vaccine uptake by type among 
children over three recent flu seasons with different children sampled each year. 
For the 2014-2015 flu season, a relationship between age, race, family income, 
and vaccine type (LAIV/ IIV) was established among U.S. children included in this 
study. Those who received LAIV were most likely to be White elementary school age 
children with a family income of 75,000+ for all the flu seasons included in this study. 
The 2015-2016 and 2016-2017 flu seasons showed a relationship between demographic 
characteristics (age and race) and vaccine type (LAIV/ IIV). However, socioeconomic-
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demographic status was not considered influential in LAIV uptake for race, health 
insurance status, or family income. Based on the results, ACIP recommendations by age 
and year had the greatest impact on flu vaccine choice for this sample population. 
Interpretation of the Findings  
The findings of this study extend the current knowledge about flu vaccine uptake 
in the community by addressing issues associated with flu vaccine choice. Most flu 
vaccine research has evaluated the efficacy of the vaccine based on a test-negative design 
(a variation of the case-control design). Few studies have evaluated influenza vaccine 
uptake by type, socioeconomic status, demographic characteristics, and ACIP 
recommendations. Thus, this study adds to current knowledge regarding influenza 
vaccine uptake among children by identifying socioeconomic factors and demographic 
characteristics that influence LAIV uptake in the community in addition to the impact of 
ACIP recommendations on vaccine choice.  
Perceptions of safety and efficacy are determining factors regarding seasonal flu 
vaccination uptake (Galarce et al., 2011). For roughly 50% of flu vaccinated children, 
parents reported no preference for either IIV or LAIV for both the 2014-2015 and 2015-
2016 flu seasons (Santibanez, Kahn, & Bridges, 2018) The percentage who preferred 
LAIV for 2014-2015 was 22.7%, and for 2015-2016 it was 21.7%, with 70% of those 
preferring this method citing children’s fear of needles (Santibanez et al., 2018). Further, 
the percentage of parents with a preference for IIV for 2014-2015 was 22.1%, and for 
2015-2016 it was 24.7% (Santibanez et al., 2018).   
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The current study showed that most children who received the LAIV were within 
the age range recommended by the ACIP of 2-8 across all three flu seasons. In addition, 
children 6-8 years of age consistently received the LAIV vaccine across all three seasons 
with an average of 24.1% coverage, though the ACIP recommended no one receive the 
LAIV vaccine for the 2016-2017 flu season. The American Academy of Pediatrics 
recommended preference for the IIV vaccine for the 2018-2019 flu season but encourages 
parents to vaccinate their children for the flu regardless of vaccine type, because 
receiving the nasal vaccine is better than no vaccine (Munoz, 2018).  
Additional findings from this study are that race was indicated as a determining 
factor for choice between IIV and LAIV for each individual flu season. White children, 
who were vaccinated for the flu, were more likely to receive LAIV than other races 
included in this study. This is consistent with a recent study that showed White adult 
Americans are more likely to receive the flu vaccine than other racial groups, especially 
those with higher income (Abbas, Kang, Chen, Werre, & Marathe, 2018). This has 
implications for improving vaccine uptake among adults by,  
increasing awareness of the safety, efficacy and need for influenza vaccination, 
leveraging the practices and principles of commercial and social marketing to 
improve vaccine trust, confidence and acceptance, and lowering out-of-pocket 
expenses and covering influenza vaccination costs through health insurance. 
(Abbas et al., 2018, p.2).  
These suggestions are consistent with the results of this study as well.  
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Limitations of the Study  
Cross-sectional quantitative research is used to investigate the relationship 
between variables in their natural environment rather than a laboratory setting (Polit & 
Hungler, 1999). This type of investigation often involves data from descriptive studies to 
formulate hypotheses, determine a relationship between variables, and test theories. 
Cross-sectional studies are used to evaluate the nature of relationships that exist and not 
infer causality like traditional experimental studies (Creswell, 2012).  
The data from the NHIS survey are cross-sectional, based on an annual sample 
representing a changing cohort of subjects. In this case, the NHIS does not collect 
information from all subgroup populations, omitting institutionalized individuals 
including military families. One limitation is that this data are secondary, so the health 
information collected does not include verifiable medical data or laboratory data (see 
Rolnick et al., 2013). Some survey respondents may not be forthcoming about a behavior 
many consider to be undesirable. Therefore, another limitation to this study is the use of 
self-reported data, which involves setbacks such as reembrace error, reporting bias, 
incorrect documentation, and loss of cases. 
The greatest limit in this study involved measuring a relationship among 
variables, which is the assumption of generalizability. Although statistical analysis of 
data sets may reveal that two variables vary together, it does not mean they do. If the data 
are not representative of the real population, study results could indicate a relationship 
among variables that does not exist in the actual population. There are several unknown 
factors called confounders that can be unaccounted for resulting in a false perception of a 
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relationship among variables (Oleckno, 2002). In this study, potential confounders were 
evaluated to try and control for these factors. However, other unknown factors could have 
contributed to confounding not addressed in this study.  
Recommendations  
Further research is needed to evaluate the relationship among socioeconomic 
status, demographic characteristics, ACIP recommendations, and Flu vaccine uptake in 
the Community. While it is important to provide efficacy information to all parties 
involved in providing flu vaccines to the community, it is also important to determine 
what factors contribute to uptake especially among children who are most likely to be 
infected with flu and transmit it to someone else. According to the CDC’s FluView 
Influenza-Associated, pediatric mortality is highest between five and eleven years of age, 
especially when combined with a secondary bacterial infection (CDC, 2016). School-age 
children have the highest influenza transmission and infection rate, ranging from a 10-40 
% attack rate yearly (Wilson et al., 2013). Over half of all flu vaccines in the U.S. are 
administered to individuals ages 6 months to 17 years old (Peng-jun Lu et al., 2013). 
According to the Morbidity and Mortality Weekly Report, the United States vaccination 
coverage is consistently below the Healthy People 2020 goal of 70 % (Peng-jun Lu et al., 
2013). 
In addition to the reported inconsistencies in flu vaccine efficacy, annual 
influenza immunization recommendations have varied in children 2-8 years of age. 
Inconsistencies in vaccine recommendations can negatively impact vaccine uptake in the 
community by diminishing the patients perceived benefits of following vaccine 
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recommendations (Mueller, Hill, Fontanesi, & Kopald, 2007). Studies show parents who 
delayed and refused vaccine doses were more likely to have vaccine safety concerns and 
perceive fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney & 
John, 2013; Smith et al., 2011). 
Implications for Professional Practice and Social Change  
The discontinued recommendation of LAIV for children in the U.S. has the 
potential to affect influenza vaccine uptake and community outcomes due to the theory of 
herd immunity and the transmission rate of illness from child to caregiver. LAIV was 
developed to address issues associated with production and dissemination of IIV for 
potential influenza pandemics (Penttinen & Friede, 2016). Production of IIV is timely 
and administering the vaccine requires basic safety and infection control measures due to 
its injectable nature. The LAIV option was initially determined to be ideal for mass 
vaccination of children especially in a pandemic situation due to its superior efficacy, 
ease of administration, greater production yield, rapid availability for unanticipated 
serotypes, and user-friendly application (Penttinen & Friede, 2016). Discontinuation of 
LAIV recommendations has the potential to greatly impact the community by reducing 
the number of children effectively vaccinated against the flu resulting in an increase of 
influenza exposure in the community. 
Policies can directly influence the other levels by altering and influencing the 
access and desire of flu vaccinations by making them unavailable, altering access, 
reducing their perceived effectiveness, limiting affordability, or indicating belief of risk 
associated with their use. The discontinued ACIP recommendation of the LAIV has the 
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potential to negatively influence influenza vaccine uptake in general if the underlying 
cause of LAIV’s reduced efficacy is not defined and addressed due to conflicting policy, 
and inconsistent recommendations by governing bodies, local health departments, and 
family practitioners. Improving vaccine recommendations and policy may lead to 
increased vaccine uptake and result in fewer sick days, reduced suffering, increased 
productivity, lower health cost and reduced illness and death associated with the flu virus 
especially for those most at risk. 
The potential contribution of this study is to add to current knowledge regarding 
influenza recommendations and influenza vaccine uptake among children. This study 
found that age and ACIP recommendations influence flu vaccine uptake in the 
community. Additionally, it was concluded that family income and race might also play a 
significant part in flu vaccine choice by type. Most flu vaccine research evaluates the 
efficacy of the vaccine based on a test-negative design. Few studies evaluate influenza 
vaccine uptake and ACIP recommendations. This study aimed to assess how ACIP 
recommendations influence influenza vaccination rates among children in the United 
States over the three most recent flu seasons. 
Vaccination uptake is significantly influenced by social and psychological factors, 
some of which are under-reported and poorly understood (Wheelock, Miraldo, Parand, 
Vincent, & Sevdalis, 2014). Although structural barriers are known to limit vaccination 
rates, social and psychological factors can also affect the decision to vaccinate children. 
Perceptions about flu susceptibility and vaccine effectiveness significantly influence 
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vaccination adoption (Wheelock et al., 2014). Evaluating current procedures and policies 
could improve patient perceptions and access.  
High vaccination coverage reduces exposure of unvaccinated persons to infection, 
resulting in indirect protection in addition to direct protection for the those vaccinated 
(Glezen, Gaglani, Kozinetz, & Piedra, 2010). The direct effect of immunity reduces 
infection rates among vaccinated individuals resulting in less infection circulating in the 
community, less influenza exposure, resulting in herd immunity by indirect means (Fine 
et al., 2011). Increasing the number of school-age children immunized against the flu also 
increases herd immunity by the indirect protection of household and community 
members (Lind et al., 2014). 
Conclusion  
Seasonal influenza outbreaks are associated with considerable morbidity and 
mortality in the United States (Hull & Ambrose, 2011; Weycker et al., 2005; Wilson et 
al., 2013). Annual fall influenza vaccinations are the most effective method for 
preventing influenza and its complications (Weycker et al., 2005). According to the 
CDC’s FluView Influenza-Associated, Pediatric Mortality is highest between five and 
eleven years of age, especially when combined with a secondary bacterial infection 
(CDC, 2016). Yet annual influenza attack rates among school-age children, who play a 
fundamental role in transmitting the infection to others, are as high as 42 % (Carpenter et 
al., 2007). 
 The vaccination of children has been shown to reduce the impact of influenza on 
the communities where they reside, which is of particular importance for at-risk 
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populations such as those 65 years of age and older (Wilson, Sanchez, Blackwell, 
Weinstein, & El Amin, 2013). Seasonal influenza is estimated to impact 10-20 % of the 
United States population annually (Hull & Ambrose, 2011). The flu is rapidly transmitted 
in large populations with close contact, especially in the fall and winter months during 
the traditional academic school year. School-age children have the highest influenza 
transmission and infection rate, ranging from a 10 to 40 % attack rate yearly (Wilson et 
al., 2013). The World Health Organization recommends a seasonal flu vaccination 
consisting of a 75 % coverage rate for high-risk populations (Longini & Halloran, 2005). 
In addition to the reported inconsistencies in Flu vaccine efficacy, annual 
influenza immunizations recommendations have varied dramatically in children 2-8 years 
of age. Inconsistencies in vaccine recommendations can negatively impact vaccine 
uptake in the community by diminishing the patients perceived benefits of following 
vaccine recommendations (Mueller et al., 2007). Studies show parents who delayed and 
refused vaccine doses were more likely to have vaccine safety concerns and perceive 
fewer benefits associated with these vaccines (Blyth et al., 2014; Cheney & John, 2013; 
Smith et al., 2011). 
 
 
85 
 
References 
Abbas, K. M., Kang, G. J., Chen, D., Werre, S. R., & Marathe, A. (2018). Demographics, 
perceptions, and socioeconomic factors affecting influenza vaccination among 
adults in the United States. PeerJ, 6, e5171. https://doi.org/10.7717/peerj.5171 
Belshe, R. B., Edwards, K. M., Vesikari, T., Black, S. V., Walker, R. E., Hultquist, M., . . 
. Connor, E. M. (2007). Live attenuated versus inactivated influenza vaccine in 
infants and young children. New England Journal of Medicine, 356(7), 685–696. 
https://doi.org/10.1056/NEJMoa065368 
Blair, R. C., & Taylor, R. A. (2008). Biostatistics for the health sciences. Upper Saddle 
River, NJ: Pearson Prentice Hall. 
Blyth, C. C., Richmond, P. C., Jacoby, P., Thornton, P., Regan, A., Robins, C., . . . Effler, 
P. V. (2014). The impact of pandemic A(H1N1)pdm09 influenza and vaccine-
associated adverse events on parental attitudes and influenza vaccine uptake in 
young children. Vaccine, 32(32), 4075–4081. 
https://doi.org/10.1016/j.vaccine.2014.05.055 
Carpenter, L. R., Lott, J., Lawson, B. M., Hall, S., Craig, A. S., Schaffner, W., & Jones, 
T. F. (2007). Mass distribution of free, intranasally administered influenza 
vaccine in a public school system. Pediatrics, 120(1), e172–178. 
https://doi.org/10.1542/peds.2006-2603 
Caspard, H., Gaglani, M., Clipper, L., Belongia, E. A., McLean, H. Q., Griffin, M. R., . . . 
Ambrose, C. S. (2016). Effectiveness of live attenuated influenza vaccine and 
inactivated influenza vaccine in children 2–17 years of age in 2013–2014 in the 
86 
 
United States. Vaccine, 34(1), 77–82. 
https://doi.org/10.1016/j.vaccine.2015.11.010 
Centers for Disease Control and Prevention. (2014). ACIP grading for LAIV in children 
ages 2-8. Retrieved from https://www.cdc.gov/vaccines/acip/recs/grade/laiv-
child.html 
Centers for Disease Control and Prevention. (2015). 2014 National Health Interview 
Survey (NHIS) Public Use Data Release. Retrieved from 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/201
4/srvydesc.pdf 
Centers for Disease Control and Prevention. (2016). National Immunization Survey-Child 
Influenza Module (NIS-CIM). Retrieved from https://www.cdc.gov/vaccines/imz-
managers/nis/downloads/nis-childquestionnaire-2016.pdf 
Centers for Disease Control and Prevention. (n.d.). About the national immunization 
surveys. Retrieved from https://www.cdc.gov/vaccines/imz-
managers/nis/about.html 
Chen, J. Y., Fox, S. A., Cantrell, C. H., Stockdale, S. E., & Kagawa-Singer, M. (2007). 
Health disparities and prevention: Racial/ethnic barriers to flu vaccinations. 
Journal of Community Health, 32(1), 5–20. https://doi.org/10.1007/s10900-006-
9031-7 
Cheney, M. K., & John, R. (2013). Underutilization of influenza vaccine: A test of the 
health belief model. SAGE Open, 3(2), 2158244013484732. 
https://doi.org/10.1177/2158244013484732 
87 
 
Chung, J. R., Flannery, B., Thompson, M. G., Gaglani, M., Jackson, M. L., Monto, A. S., 
. . . Fry, A. M. (2016). Seasonal effectiveness of live attenuated and inactivated 
influenza vaccine. PEDIATRICS, 137(2), e20153279–e20153279. 
https://doi.org/10.1542/peds.2015-3279 
Deyle, E. R., Maher, M. C., Hernandez, R. D., Basu, S., & Sugihara, G. (2016). Global 
environmental drivers of influenza. Proceedings of the National Academy of 
Sciences, 113(46), 13081–13086. https://doi.org/10.1073/pnas.1607747113 
Eick-Cost, A. A., Tastad, K. J., Guerrero, A. C., Johns, M. C., Lee, S., MacIntosh, V. H., 
. . . Sanchez, J. L. (2012). Effectiveness of seasonal influenza vaccines against 
influenza-associated illnesses among U.S. military personnel in 2010–11: A case-
control approach. PLoS ONE, 7(7). https://doi.org/10.1371/journal.pone.0041435 
Fine, P., Eames, K., & Heymann, D. L. (2011). “Herd immunity”: A rough guide. 
Clinical Infectious Diseases, 52(7), 911–916. https://doi.org/10.1093/cid/cir007 
Flannery, B., & Chung, J. (2016). Influenza vaccine effectiveness, including LAIV vs IIV 
in children and adolescents, U.S. Flu VE Network, 2015–16. Advisory Committee 
on Immunization Practices, 22. Retrieved from 
http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-
05-flannery.pdf 
Flannery, B., Chung, J. R., Thaker, S. N., Monto, A. S., Martin, E. T., Belongia, E. A., . . 
. Fry, A. M. (2017). Interim estimates of 2016–17 seasonal influenza vaccine 
effectiveness — United States, February 2017. Morbidity and Mortality Weekly 
Report, 66(6), 167–171. https://doi.org/10.15585/mmwr.mm6606a3 
88 
 
Frankfort-Nachmias, C., & Nachmias, D. (2008). Research methods in the social 
sciences. New York, NY: Worth. 
Frew, P. M., Hixson, B., Rio, C. del, Esteves-Jaramillo, A., & Omer, S. B. (2011). 
Acceptance of pandemic 2009 influenza A (H1N1) vaccine in a minority 
population: Determinants and potential points of intervention. Pediatrics, 
127(Supplement 1), S113–S119. https://doi.org/10.1542/peds.2010-1722Q 
Galarce, E. M., Minsky, S., & Viswanath, K. (2011). Socioeconomic status, 
demographics, beliefs and A(H1N1) vaccine uptake in the United States. Vaccine, 
29(32), 5284–5289. https://doi.org/10.1016/j.vaccine.2011.05.014 
Glezen, W. P., Gaglani, M. J., Kozinetz, C. A., & Piedra, P. A. (2010). Direct and 
indirect effectiveness of influenza vaccination delivered to children at school 
preceding an epidemic caused by 3 new influenza virus variants. The Journal of 
Infectious Diseases, 202(11), 1626–1633. https://doi.org/10.1086/657089 
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. 
B., & Bresee, J. S. (2016). Prevention and control of seasonal influenza with 
vaccines: Recommendations of the Advisory Committee on Immunization 
Practices — United States, 2016–17 Influenza Season. Morbidity and Mortality 
Weekly Report, 65. https://doi.org/10.15585/mmwr.rr6505a1 
Hamborsky, J., Kroger, A., & Wolfe, C. (2015). Epidemiology and prevention of vaccine-
preventable diseases. Washington, DC: Public Health Foundation. 
Harris, J. K., Mansour, R., Choucair, B., Olson, J., Nissen, C., Bhatt, J. (2014). 
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations 
89 
 
of the Advisory Committee on Immunization Practices (ACIP) — United States, 
2014–15 Influenza Season. Morbidity and Mortality Weekly Report, 63(32), 681–
685. Retrieved from https://www.cdc.gov/mmwr/pdf/wk/mm6332.pdf 
Jayasundara, K., Soobiah, C., Thommes, E., Tricco, A. C., & Chit, A. (2014). Natural 
attack rate of influenza in unvaccinated children and adults: A meta-regression 
analysis. BMC Infectious Diseases, 14, 670. https://doi.org/10.1186/s12879-014-
0670-5 
Kahn, K. E., Santibanez, T. A., Zhai, Y., & Singleton, J. A. (2015). Influenza vaccination 
type, live, attenuated influenza vaccine (LAIV) versus inactivated influenza 
vaccine (IIV), received by children, United States, 2011−12 through 2013−14 
influenza seasons. Vaccine, 33(39), 5196–5203. 
https://doi.org/10.1016/j.vaccine.2015.07.064 
Kelly, H., Carville, K., Grant, K., Jacoby, P., Tran, T., & Barr, I. (2009). Estimation of 
influenza vaccine effectiveness from routine surveillance data. PLOS ONE, 4(3), 
e5079. https://doi.org/10.1371/journal.pone.0005079 
Kumar, S., Quinn, S. C., Kim, K. H., Musa, D., Hilyard, K. M., & Freimuth, V. S. 
(2012). The social ecological model as a framework for determinants of 2009 
H1N1 influenza vaccine uptake in the United States. Health Education & 
Behavior, 39(2), 229–243. https://doi.org/10.1177/1090198111415105 
Laerd Statistics. (2015). Binomial logistic regression using SPSS Statistics. Retrieved 
from https://statistics.laerd.com/ 
Laerd Statistics. (2017). Chi-square test of homogeneity (2 x C) using SPSS Statistics. 
90 
 
Retrieved from https://statistics.laerd.com/ 
Lanthier, P. A., Huston, G. E., Moquin, A., Eaton, S. M., Szaba, F. M., Kummer, L. W., . 
. . Haynes, L. (2011). Live attenuated influenza vaccine (LAIV) impacts innate 
and adaptive immune responses. Vaccine, 29(44), 7849–7856. 
https://doi.org/10.1016/j.vaccine.2011.07.093 
Lind, C., Russell, M. L., MacDonald, J., Collins, R., Frank, C. J., & Davis, A. E. (2014). 
School-based influenza vaccination: parents’ perspectives. PLOS ONE, 9(3), 
e93490. https://doi.org/10.1371/journal.pone.0093490 
Longini, I. M., & Halloran, M. E. (2005). Strategy for distribution of influenza vaccine to 
high-risk groups and children. American Journal of Epidemiology, 161(4), 303–
306. https://doi.org/10.1093/aje/kwi053 
Matrajt, L., Halloran, M. E., & Antia, R. (2018). Successes and failures of the live-
attenuated influenza vaccine, can we do better? BioRxiv. 
https://doi.org/10.1101/424275 
MedImmune. (2016). FluMist Quadrivalent Package Insert. Retrieved from 
http://www.azpicentral.com/flumistquadrivalent/flumistquadrivalent.pdf#page=1 
Mueller, M.-R., Hill, L., Fontanesi, J., & Kopald, D. (2007). Disagreement on 
immunization recommendations: An analysis of lay-clinician interaction. Journal 
of Applied Social Science, 1(2), 69–76. 
https://doi.org/10.1177/193672440700100206 
Munoz, F. (2018). American Academy of Pediatrics advises parents to choose the flu shot 
for 2018-2019 flu season. Retrieved from https://www.aap.org/en-us/about-the-
91 
 
aap/aap-press-room/Pages/AAP-Advises-Parents-to-Choose-the-Flu-Shot-For-
2018-2019-Flu-Season.aspx 
National Center for Health Statistics. (2015a). National Health Interview Survey, 2015. 
Public-use data file and documentation. Retrieved from 
https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm 
National Center for Health Statistics. (2015b). Survey Description, National Health 
Interview Survey, 2015. Hyattsville, Maryland. 
National Center for Health Statistics. (2016a). National Health Interview Survey, 2016. 
Public-use data file and documentation. Retrieved from 
https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm 
National Center for Health Statistics. (2016b). Survey Description, National Health 
Interview Survey, 2016. Retrieved from 
https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/20
16/srvydesc.pdf 
National Center for Health Statistics. (2017a). National Health Interview Survey, 2017. 
Public-use data file and documentation. Retrieved from 
https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm 
National Center for Health Statistics. (2017b). Survey Description, National Health 
Interview Survey, 2017. Retrieved from 
https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/20
17/srvydesc.pdf 
Oleckno, W. A. (2002). Essential epidemiology: principles and applications. Prospect 
92 
 
Heights, IL: Waveland. 
Peng-jun Lu, Tammy A. Santibanez, Walter W. Williams, Jun Zhang, Helen Ding, Leah 
Bryan, & Alissa O’Halloran. (2013). Surveillance of Influenza Vaccination 
Coverage — United States, 2007–08 Through 2011–12 Influenza Seasons. 
Retrieved from 
http://www.cdc.gov/mmwr/preview/mmwrhtml/ss6204a1.htm?s_cid%3Dss6204a
1_x 
Penttinen, P. M., & Friede, M. H. (2016). Decreased effectiveness of the influenza 
A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias 
or a technical challenge? Eurosurveillance, 21(38). https://doi.org/10.2807/1560-
7917.ES.2016.21.38.30350 
Rhorer, J., Ambrose, C. S., Dickinson, S., Hamilton, H., Oleka, N. A., Malinoski, F. J., & 
Wittes, J. (2009). Efficacy of live attenuated influenza vaccine in children: A 
meta-analysis of nine randomized clinical trials. Vaccine, 27(7), 1101–1110. 
https://doi.org/10.1016/j.vaccine.2008.11.093 
Robinson, C. L. (2016). Advisory Committee on Immunization Practices Recommended 
Immunization Schedules for Persons Aged 0 Through 18 Years-United States, 
2016. American Journal of Transplantation, 16(6), 1928–1929. 
https://doi.org/10.1111/ajt.13858 
Rolnick, S. J., Parker, E. D., Nordin, J. D., Hedblom, B. D., Wei, F., Kerby, T., … Euler, 
G. (2013). Self-report compared to electronic medical record across eight adult 
vaccines: Do results vary by demographic factors? Vaccine, 31(37), 3928–3935. 
93 
 
https://doi.org/10.1016/j.vaccine.2013.06.041 
Rose, M. A., Damm, O., Greiner, W., Knuf, M., Wutzler, P., Liese, J. G., … Eichner, M. 
(2014). The epidemiological impact of childhood influenza vaccination using 
live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation 
study. BMC Infectious Diseases, 14(1). https://doi.org/10.1186/1471-2334-14-40 
Santibanez, T. A., Kahn, K. E., & Bridges, C. B. (2018). Do parents prefer inactivated or 
live attenuated influenza vaccine for their children? Vaccine. 
https://doi.org/10.1016/j.vaccine.2018.10.042 
Smith, P. J., Humiston, S. G., Marcuse, E. K., Zhao, Z., Dorell, C. G., Howes, C., & 
Hibbs, B. (2011). Parental Delay or Refusal of Vaccine Doses, Childhood 
Vaccination Coverage at 24 Months of Age, and the Health Belief Model. Public 
Health Reports, 126(2_suppl), 135–146. 
https://doi.org/10.1177/00333549111260S215 
Sultana, I., Yang, K., Getie-Kebtie, M., Couzens, L., Markoff, L., Alterman, M., & 
Eichelberger, M. C. (2014). Stability of neuraminidase in inactivated influenza 
vaccines. Vaccine, 32(19), 2225–2230. 
https://doi.org/10.1016/j.vaccine.2014.01.078 
Tricco, A. C., Chit, A., Soobiah, C., Hallett, D., Meier, G., Chen, M. H., … Loeb, M. 
(2013). Comparing influenza vaccine efficacy against mismatched and matched 
strains: a systematic review and meta-analysis. BMC Medicine, 11(1). 
https://doi.org/10.1186/1741-7015-11-153 
Weycker, D., Edelsberg, J., Elizabeth Halloran, M., Longini, I. M., Nizam, A., Ciuryla, 
94 
 
V., & Oster, G. (2005). Population-wide benefits of routine vaccination of 
children against influenza. Vaccine, 23(10), 1284–1293. 
https://doi.org/10.1016/j.vaccine.2004.08.044 
Wheelock, A., Miraldo, M., Parand, A., Vincent, C., & Sevdalis, N. (2014). Journey to 
vaccination: a protocol for a multinational qualitative study. BMJ Open, 4(1), 
e004279. https://doi.org/10.1136/bmjopen-2013-004279 
Wilson, D., Sanchez, K. M., Blackwell, S. H., Weinstein, E., & El Amin, A. N. (2013). 
Implementing and Sustaining School-Located Influenza Vaccination Programs: 
Perspectives From Five Diverse School Districts. The Journal of School Nursing, 
29(4), 303–314. https://doi.org/10.1177/1059840513486011 
 
